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Constitutive activation of the PI3-K/Akt pathway is known to be the major 
survival pathway in LNCaP, a prostate cancer model, which has a frameshift mutation in 
the PTEN gene resulting in a defective PTEN. Recent studies have shown that PI3-K/Akt 
independent survival pathways existed in LNCaP as apoptosis triggered by PI3-K 
inhibitors, in serum-free conditions, can be blocked by the addition of growth factors 
such as androgen. In this study, we showed that the PI3-K/Akt independent survival 
pathway in LNCaP mediated by androgen was due to its genomic effect and the 
expression of the androgen receptor was essential. Exposure of LNCaP cells to androgen 
led to an increase in the anti-apoptotic protein Bcl-xL expression and silencing of Bcl-xL 
gene expression in LNCaP, using the siRNA strategy, abolished the anti-apoptotic 
signaling mediated by androgen in the presence of a PI3-K inhibitor, LY294002. Thus 
these findings indicated that Bcl-xL plays a role in the survival pathway mediated by 
androgen.  
Interestingly, STAT3 has been shown to be involved in the activation of Bcl-xL 
expression. Androgen induced up-regulation of Bcl-xL was paralleled by a similar 
increase in STAT3 activation. Furthermore, repression of STAT3 blocked the androgen-
induced Bcl-xL expression and the rescue of LNCaP cells from apoptosis induced by 
inhibition of PI3-K. Our results also showed that the increase in Bcl-xL expression was 
involved in the inhibition of Bak activated by blocking PI3-K/AKT signaling. This was 
mediated by an increase in Bcl-xL and Bak interactions which is likely to prevent Bak 
oligomerization. Hence these results suggested that the androgen mediated protection of 
LNCaP from apoptosis triggered by the inhibition of PI3-K pathway could probably be 
 vii
due to the up-regulation of Bcl-xL protein, through the activation of STAT3, which could 
associate with Bak and inhibit its activity to cause cell death. 
Moreover the study of androgen-independent LNCaP sub-line which has lost its 
androgen receptor expression demonstrated constitutive activation of the MAPK 
signaling in addition to the PI3-K/AKT signaling. Experimental and computational 
model-simulated results suggested that this could likely be due to a cross-talk, absent in 
androgen-dependent LNCaP, between both signaling pathways whereby PDK1 could 
activate MEK.  
Taken together, our study provided evidence to propose a mechanism for 
androgen-mediated cell survival in LNCaP and to understand the development of 
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1.   INTRODUCTION 
1.1.   Androgen receptor 
1.1.1   Androgen  
 Androgen is important for the development of male sexual organs and male 
secondary sexual characteristics. The most important circulating androgen, testosterone, 
is secreted by Leydig cells in the testes. However, a small amount of androgen is also 
produced by the adrenal cortex as dehydroepiandrosterone (DHEA).  
Circulating testosterone enters the cells by diffusion and is converted into a more 
potent form, dihydrotestosterone (DHT), by 5α-reductase. DHT binds to the androgen 
receptor (AR), thereby activating the androgen signaling pathway (So et al, 2003). The 
synthetic androgen, methyltrienolone R1881, has greater binding affinity to the androgen 
receptor than DHT and testosterone. The relative binding affinities of these androgens to 
the AR parallels their effects on cell growth (Schuurmans et al, 1988).   
 
1.1.2   Structure of androgen receptor (AR) 
AR belongs to the nuclear receptor family and is a ligand-dependent transcription 
factor. AR regulates the expression of genes for male sexual development and 
maintenance of accessory sexual organs. Thus AR is important for the normal function 
and differentiation of the prostate. AR has also been implicated in the development of 
prostate cancer but the precise mechanism remains unclear (Culig et al, 2002). 
AR is made up of three domains: the N terminal domain which is responsible for 
the regulation of the AR transcriptional activity; a central DNA-binding domain which 
contains two zinc fingers that interact with the androgen response element (ARE); and a 
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ligand-binding domain which binds to androgen and anti-androgen. The DNA-binding 
and ligand-binding domain are separated by the hinge region which is involved in the 
translocation of AR from the cytoplasm to the nucleus (Culig et al, 2002). 
 
1.1.3   AR signaling 
In the absence of its physiological ligand, AR is maintained in an inactive state 
via binding to several heat-shock proteins (HSP), such as HSP-70 and HSP-90, in the 
cytoplasm.  HSPs serve to maintain AR structure and protect it from degradation. Once 
bound to the ligand, AR changes its conformation and loses its affinity for HSPs. The 
ligand-binding domain and the N-terminal domain of a single AR interact intra-
molecularly to form an active AR and this process may involve the role of co-factors. 
Active AR undergoes homodimerization either in the cytoplasm or more efficiently in the 
nucleus (Schaufele et al, 2005).  
Besides undergoing homodimerization, the ligand binding to AR also promotes 
the recruitment of several kinases to phosphorylate AR at specific sites. It is suggested 
that phosphorylation of the AR may influence the stability of the AR homodimers and its 
transactivation. However it is still unclear if different phosphorylation sites on the AR are 
associated with different functions (Edwards and Bartlett, 2005).  
AR homodimers are able to translocate to the nucleus and bind to the androgen 
response element present at the promoter region of androgen responsive genes. AR co-
activators are recruited to the promoter region to facilitate the assembly of the pre-
initiaiton complex for transcription. AR co-activators can alter AR transcriptional activity 
and ligand specificity. Together with AR co-activators, AR dimers regulate the 
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transcription of androgen-dependent genes (Wong et al, 1993; Edwards and Bartlett, 
2005).  
Anti-androgens, such as flutamide, inhibit AR signaling by binding to AR at the 
ligand-binding domain leading to a conformational change which is different from 
androgen-bound AR. Thus flutamide inactivates AR by preventing flutamide-bound AR 
to homodimerize or by forming flutamide-bound AR and androgen-bound AR 
heterodimer, which are unable to bind to DNA to activate gene transcription (Navarro et 
al, 2002).  
In addition to its role as a ligand-inducible transcription factor in the nucleus, AR 
can also induce rapid non-genomic signaling responses. AR was first demonstrated to 
activate mitogen-activated protein kinase (MAPK) independent of its transcriptional 
activity. In contrast to the conventional transcriptional effect of AR, the activation of 
MAPK by AR is a rapid process which is insensitive to the anti-androgen 
hydroxyflutamide (Peterziel et al, 1999). Another study showed that DHT could rapidly 
activate the steroid receptor co-activator (Src)/mitogen-activated protein kinase kinase 
(MEK)/extracellular signal-regulated kinase (ERK)/cAMP response element binding 
protein (CREB) signaling pathway through AR leading inhibition of apoptosis even in 
mutants lacking a functioning DNA-binding domain (Unni et al, 2004). In addition to 
non-genomic activation of MAPK, there is evidence indicating that androgens trigger AR 
activation and interaction with phosphatidylinositol 3-OH kinase (PI3-K) leading to PI3-




1.2   Prostate cancer 
1.2.1   Prostate cancer and its treatment  
Prostate cancer is one of the most common tumours of males. It is the second 
leading cause of cancer death in men in the United States and the United Kingdom 
(American Cancer Society, 2004 and www.prostate-research.org.uk). Age is one of the 
most important risk factors (Wynder et al, 1971) as its clinical diagnosis increases with 
age. Genetic risk factors are likely to contribute to the disease as studies have suggested 
an increase in the risk of development in male relatives of men with prostate cancer 
(Lesko et al, 1996). Other major risk determinants include environmental factors, 
particularly nutrition. 
 The prostate is a ductal-acinar gland and androgens induce its development which 
ends with sexual maturity. The human prostate is divided into three zones: central, 
peripheral and transitional. This is different from most other animals including rodents 
and primates in which the prostate is subdivided into lobes. Therefore this poses a 
challenge in the development of an animal model to study prostate pathology. Prostate 
tumours occur mostly in the peripheral zone, the largest region of the prostate which is 
mainly made up of ducts and acini lined with columnar epithelium (Cunha et al, 2003). 
It was demonstrated as early as 1941 that early stages of prostate cancer were 
hormone-dependent and androgen withdrawal resulted in tumour regression (Huggin et 
al, 1941). Treatment of early stages of prostate cancer includes androgen ablation, 
prostatectomy and radiotherapy. However, prostate tumours can develop resistance to 
prolonged androgen ablation therapy and advance to a hormone-independent stage which 
is associated with high mortality (Pilat et al, 1999). 
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1.2.2   Androgen-independent prostate cancer 
The exact mechanism leading to the development of androgen-independent 
prostate cancer is still obscure. It is likely to be a multi-step process requiring defects in 
various growth regulatory signals. Recent findings have suggested several possible 
explanations for the development of androgen independence. One third of androgen-
independent tumours have AR gene amplification leading to a higher expression of the 
AR protein than androgen-dependent tumours. Thus the overexpression of AR may 
sensitize AR to activation by low levels of androgen, probably enabling prostate tumours 
to survive following androgen ablation (Linja et al, 2001).  Mutations in the AR leading 
to its activation by other non-androgenic ligands such as estrogen or non-steroidal anti-
androgens can also contribute to androgen independence. Several studies also showed 
that AR activity could be modified by AR cofactors or phosphorylation by AKT and 
MAPK signaling pathways leading to AR activation in the presence of low androgen 
after androgen ablation (Edwards and Bartlett, 2005). One report showed that the 
progression of LNCaP cells to the androgen-independent state required intact PI3-K 
signaling (Murillo et al, 2001). However, more evidence is required to confirm the 
transition to androgen independence of prostate cancer cells. The molecular events, 
which drive prostate tumours to becoming insensitive to androgen ablation, remain vague 
and their understanding could be the key to refine treatment of late stage prostate cancer.  
 
1.2.3   Androgen-dependent prostate cancer model, LNCaP 
The LNCaP cell line is derived from a metastatic lesion of human prostate cancer 
(Horoszewicz et al, 1983) and remains one of the most commonly used in vitro models in 
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prostate cancer studies. AR signaling is essential for the survival of the androgen-
sensitive LNCaP cells. The suppression of AR expression by siRNA techniques in 
LNCaP cells blocked proliferation and led to apoptosis (Yang et al, 2005). Bicalutamide, 
an anti-androgen, has been shown to interfere with androgen receptor-mediated survival 
and initiate cell death in LNCaP cells (Lee et al, 2003).  
The LNCaP cell line contains a frameshift mutation in the phosphatase and tensin 
homolog PTEN gene (Vlietstra et al, 1998). The loss of PTEN, a phosphatase which 
dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3) to phosphatidylinositol 
4,5-biphosphate (PIP2), leads to constitutively active PI3-K activity which 
phosphorylates PIP2 to PIP3. PIP3 recruits AKT to the membrane to allow AKT to be 
phosphorylated at Threonine 308 by phosphoinositide dependent kinase 1 (PDK1) (Kohn 
et al, 1996) and at Serine 473 by an unknown kinase. Controversial studies have reported 
DNA-dependent protein kinase (DNA-PK) (Feng et al, 2004) or rictor and mammalian 
target of rapamycin (mTOR) complex (Sarbassov et al, 2005) as possible candidates 
responsible for the phosphorylation of AKT at Serine 473. The PI3-K/AKT pathway is 
one of the most important survival pathways in LNCaP cells as inhibition of this pathway 
in the absence of growth factors leads to cell death.  
However, studies have shown that PI3-K/AKT independent survival pathways 
also exist in LNCaP cells since cell death induced by the inhibition of PI3-K/AKT 
signaling can be blocked by other factors such as serum, epidermal growth factor (EGF) 
and androgen (Carson et al, 1999). It has been recently reported that EGF and serum, 
through distinct pathways, inhibit the phosphorylation and translocation of Bcl2-
antagonist of cell death (Bad) to rescue LNCaP cells from apoptosis induced by inhibitor 
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of PI3-K (Chao and Clement, 2006). However, the exact mechanism of androgen-
mediated PI3-K independent cell survival remains unclear. 
 
1.3   Signal transducer and activator of transcription 3 (STAT3) signaling 
1.3.1   STAT family 
STAT proteins are important mediators of cytokines- and growth factors-induced 
signaling pathways leading to a broad range of biological processes such as proliferation, 
differentiation and survival. Currently the STAT family consists of seven members 
(STAT1-4, STAT5a, STAT5b and STAT6) with specific tissue distribution and diverse 
roles in response to extracellular ligands. STAT2, STAT4 and STAT6 are activated by a 
small number of cytokines and are involved in T-cell development and interferon-γ 
(IFNγ) signaling whereas STAT1, STAT3 and STAT5 are activated by a range of 
signaling proteins and are involved in IFN signaling, development of mammary glands 
and embryogenesis respectively. STAT1, STAT3 and STAT5 also play important roles in 
the regulation of cell cycle progression and apoptosis (Calo et al, 2003) 
The STAT transcription factor contains a transcriptional activation domain, DNA-
binding domain, src-homology 2 (SH2) domain essential for its dimerization, and 
conserved tyrosine and serine residues which upon phosphorylation lead to STAT 
activation and enhancement of its transcriptional activity respectively. 
Upon ligand binding to the receptor, the Janus kinase (JAK) binds to the 
cytoplasmic domain of the receptor and induces phosphorylation of the tyrosine residues 
on the receptor, creating STAT docking sites. STATs recruited from the cytoplasm are 
phosphorylated on specific tyrosine residues leading to their dimerization and 
Introduction 8
translocation to the nucleus. STAT dimers bind to their specific target gene promoters 
and recruit co-activators to regulate transcription (reviewed by Aaronson and Horvath, 
2002). 
The activation of STATs is negatively regulated by a few proteins. A group of 
proteins known as the protein that inhibit activated STATs (PIAS) can interact directly 
with activated STATs and block their DNA-binding ability (Calo et al, 2003). Nuclear 
tyrosine phosphatases such as TC45 can also dephosphorylate STAT leading to the decay 
of its signal and export back to the cytoplasm (Ibarra-Sanchez et al, 2000). Besides 
targeting STATs, suppressors of the cytokine signal (SOCS) family of proteins inhibit 
STATs signaling by targeting JAK kinases via recruitment to the activated receptor 
complex and blocking the downstream cascade. SOCS can also induce the degradation of 
the receptor complex by ubiquitination-mediated proteolysis (Calo et al, 2003).   
 
1.3.2   STAT3 in prostate cancer 
 Constitutive activation of STAT signaling has been linked to tumourigenesis in 
numerous malignancies including prostate cancer. It was shown that transfection with a 
constitutively activated form of STAT3 induced proliferation in LNCaP cells (DeMiguel 
et al, 2002). In particular, STAT3 has been shown to protect cells against apoptosis as 
direct inhibition of STAT3 activation induced apoptosis in prostate cancer cell lines 
(Barton et al, 2004). In addition, interleukin 6 (IL-6), a cytokine involved in cellular 
processes such as inflammation, differentiation and proliferation, was demonstrated to 
inhibit apoptosis in LNCaP cells during androgen deprivation via STAT3 activation (Lee 
et al, 2004). 
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1.3.3   STAT3 and AR signaling 
Evidence has indicated that STAT3 could play a role in AR signaling. 
Transcriptional activity of AR could be enhanced by constitutively active form of 
STAT3. Activated STAT3 also significantly increase the sensitivity of AR to androgen 
(DeMiguel et al, 2003). Conversely, AR is likely to regulate STAT3 signaling as well. It 
was found that activated AR could directly associate with STAT3 and lead to synergistic 
transactivation of STAT3-dependent genes (Matsuda et al, 2001). Activated AR was also 
reported to interact with the protein inhibitor of activated STAT3 (PIAS3), which is a 
negative regulator of STAT3 that binds to STAT3 and blocks its DNA-binding ability, to 
relieve the inhibition of PIAS3 on STAT3-mediated transcription (Yamamoto et al, 
2003). 
Furthermore, several reports provided evidence to show that IL-6 could activate 
AR-mediated gene expression in the absence of androgen via STAT3 transduction 
pathway. This was due to the activation of STAT3 by IL-6 treatment leading to a direct 
interaction of AR N-terminal domain with STAT3 in LNCaP cells (Chen et al, 2000 and 
Ueda et al, 2002).  
 
1.4   Epidermal growth factor receptor (EGFR) and prostate cancer 
1.4.1   ErbB receptor family  
EGFR (ErbB1) belongs to the ErbB receptor tyrosine kinase family. Other 
members include the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ErbB2) 
(also known as the Her2/Neu), ErbB3 and ErbB4. The receptors are each made up of an 
extra-cellular ligand-binding domain, a hydrophobic transmembrane domain and a 
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cytoplasmic tyrosine kinase-containing domain. These receptors are activated upon 
binding to their respective EGF-related peptide growth factors, leading to their homo- or 
heterodimerization and stimulation of their intrinsic tyrosine kinase activity. Activation 
of the kinase leads to phosphorylation of specific tyrosine residues within the cytoplasmic 
domain and these phosphorylated residues act as docking sites for the recruitment of 
other substrates leading to a cascade of signaling events (Olayioye et al, 2000). It has 
been established that the ErbB receptor activation can induce the activation of other 
signaling pathways such as the ras/raf/MEK/MAPK and PI3-K pathways through binding 
to the adaptor proteins (reviewed by Normanno et al, 2006). ErbB receptors play 
important roles in development, cell proliferation and survival. EGFR and ErbB2 have 
been linked to tumour progression in models of prostate (Torring et al, 2003) and breast 
cancers (Tsutsui et al, 2002). Gene amplification and overexpression of EGFR and ErbB2 
receptors is frequently observed in human carcinomas (Normannoi et al, 2006). A strong 
correlation between nuclear STAT3 and EGFR in breast cancer samples compared to 
normal breast tissues have also been reported (Berclaz et al, 2001). 
 
1.4.2   EGFR and prostate cancer 
 Androgen has been shown to induce the activation and expression of EGFR and 
this was accompanied by a repression of ErbB2 in LNCaP cells. Androgen-induced cell 
proliferation and survival against cell death caused by inhibition of PI3-K were blocked 
by specific EGFR tyrosine kinase inhibitor CGP59326, indicating the important role of 
EGFR in androgen-mediated signaling (Torring et al, 2003).  
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Another EGFR tyrosine kinase inhibitor, ZD1839 (Iressa, Gefitinib), a drug used 
for the treatment of various cancer types, was found to block proliferation of both 
androgen-dependent (LNCaP) and androgen-independent (PC3 and DU145) prostate 
cancer cells by causing cell cycle arrest at the G0/G1 phase (Sgambato et al, 2004). 
Moreover, exposure of LNCaP cells to ZD1839 together with Casodex (a non-steroidal 
anti-androgen) has been found to lead to additive blockage of prostate cancer cell growth 
(Festuccia et al, 2005). 
 The expression of EGFR has been proposed to participate in the progression of 
androgen-independent prostate cancer. Higher expression of EGFR was associated with 
prostate cancer of higher Gleason scores (more advanced stage) and EGFR-positive 
prostate cancer patients were found to have a higher rate of relapse after prostatectomy 
than EGFR-negative patients (Lorenzo et al, 2002). In another study, the authors found a 
significant increase in EGFR expression in biopsies from the prostate of patients before 
the start of androgen deprivation and after the development of androgen-independent 
prostate cancer (Hernes et al, 2004). These reports further corroborate the significant 
association between EGFR expression and progression to androgen-independent prostate 
cancer.  
Furthermore, EGFR was also implicated in the invasion of various cancers. 
ZD1839 was reported to suppress the invasiveness of the human head and neck squamous 
cell carcinoma and breast cancer cells via inhibition of the c-Src and Pak pathways (Yang 
et al, 2004). Bonaccorsi et al provided evidence to support that AR could interact with 
EGFR and affect prostate cancer invasion. Expression of AR in PC3 cells decreased cell 
invasion via the interaction of AR and EGFR, thereby disrupting the interaction of EGFR 
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with integrin α6β4 which was required for cell migration and invasion (Bonaccorsi et al, 
2004).  
 
1.5   Bcl2 family members  
1.5.1   Regulators of apoptosis 
 Apoptosis is an essential physiological process which is tightly regulated and 
plays an important role in development and homeostasis. The dysregulation of apoptosis 
can result in diseases such as cancer, autoimmunity, degenerative diseases and 
immunodeficiency. A series of morphological changes occur during apoptosis and these 
include cell shrinkage, cell blebbing and breakdown of the nucleus.  
Apoptosis can be activated by the receptor-mediated pathway (extrinsic) or the 
mitochondria-dependent pathway (intrinsic). In the presence of apoptotic stimuli, a series 
of signal transduction events lead to the activation of caspases, a family of cysteine 
proteases that cleave proteins at specific aspartate residues. Caspases are produced as 
inactive zymogen with the pro-domains being cleaved during activation. Activated 
caspases can further cleave other caspases leading to a cascade activation of several 
executioner caspases such as caspase 3, 6 and 7 (Strasser et al, 2000; Slee et al, 2001).  
Activation of executioner caspases in turn leads to the activation or inactivation of 
a restricted set of cytoplasmic and nuclear target proteins responsible for the apoptotic 
changes such as chromatin condensation and internucleosomal DNA cleavage. These 
events culminate to inhibit DNA repair, cell cycle and mark the cell for engulfment 
(Nicholson, 1999; Strasser et al, 2000).  
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The critical regulation of apoptosis is mediated by a range of proteins including 
the B-cell leukemia/lymphoma 2 (Bcl2) protein family. All members of the Bcl2 family 
contain at least one of the four conserved motifs known as Bcl2 homology (BH) domains 
which are α-helical regions influencing their homo- and hetero-dimerization. The Bcl2 
family members can be subdivided into pro-apoptotic and anti-apoptotic members. The 
ratio of the pro-apoptotic members to anti-apoptotic members determines the cell 
commitment to apoptosis (Chao and Korsmeyer, 1998). 
 
1.5.2   Pro-apoptotic Bcl2 family proteins 
 The pro-death Bcl2 members consist of the multi-domain proteins also known as 
Bcl2-associated X protein (Bax) family (e.g. Bax, Bak and the less known Bok) and the 
BH-3 only proteins (e.g. Bad, Bid, Noxa and Puma). These two classes of pro-apoptotic 
proteins drive cell death via distinct mechanisms.  
 
1.5.2.1   Bax family 
Bax family proteins are the executioners of apoptosis and their activation by 
various stimuli is essential to mitochondria dysfunction and cell death. Cells deficient in 
Bax and Bcl-2 homologous antagonist/killer (Bak) expression are shown to be resistant to 
cell death triggers that disrupt mitochondrial functions whereas cells deficient in either 
Bax or Bak expression are still sensitive to death triggers (Wei et al, 2001). The Bax 
family proteins exist as monomers in a dormant state and activation by apoptotic stimuli 
results in their conformational change, which leads to their oligomerization and insertion 
in the mitochondrial outer membrane, triggering the release of cytochrome c and other 
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proteins. The oligomerization of Bax family proteins is the key step to drive the release of 
apoptogenic proteins from the mitochondria and this process can be promoted by the 
BH3-only proteins (Reed, 2006).  
 
Bax 
Bax mainly resides in the cytosol in the absence of death stimulus and it changes 
its conformation and translocates to the mitochondria only upon a death signal (Wolter et 
al, 1997).  The conformational change involves the exposure of the N-terminal region of 
Bax and the release of the C-terminal transmembrane region which is responsible for 
mitochondria targeting and anchoring to the outer mitochondria membrane. The C-
terminal transmembrane region is sequestered by the hydrophobic pocket formed by its 
BH1, BH2 and BH3 domains in the absence of death triggers. It has been proposed that 
the proline residue at 168 position links the N-terminal and C-terminal region of Bax and 
it may play a critical role in controlling the release of C-terminal transmembrane region 
after N-terminal exposure of Bax when apoptosis is triggered (Schinzel et al, 2004). 
However, one recent report has proposed that it may not be necessary for a major change 
in Bax conformation in order to drive death in T-cells but some intermediate form will be 
sufficient (Zhu et al, 2006). 
 
Bak 
In contrast to Bax, other members such as Bak and Bok appear to reside within 
membranes. Although Bak has been shown to localize mainly in the outer mitochondria 
membranes, it remains monomeric and inactive. Activation of Bak requires an apoptotic 
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signal, causing a conformational change which, similar to Bax, also involves the 
exposure of the concealed N-terminal epitope. The expression and localization of Bak 
remain unchanged upon apoptotic stimuli (Griffiths et al, 1999). The same author 
subsequently found out that, in addition to exposure of the Bak N-terminal, a second 
sequential conformational change involving the exposure of an epitope in Bak BH-1 
domain was required for the full activation of Bak for its pro-apoptotic properties. 
Moreover, the binding of Bak to Bcl-xL diminished as a result of unmasking Bak BH-1 
domain (Griffiths et al, 2001).  
Recently it has been reported that the inhibition of monomeric Bak as a pro-
apoptotic protein at the mitochondria membrane could be attributed to the interaction of 
voltage-dependent anion channel 2 (VDAC2) to Bak. Cells lacking VDAC2 expression 
showed an increase in Bak oligomerization and sensitivity to death triggers. The 
displacement of VDAC2 from Bak by BH3-only proteins could enhance Bak 
oligomerization leading to apoptosis (Cheng et al, 2003). Another study revealed that the 
inhibition of Bak by interaction with VDAC2 could involve Bax as this interaction was 
lost in Bax-deficient cells. However, the exact mechanism remains unclear (Chandras et 
al, 2005). 
 
1.5.2.2   BH3-only proteins 
The BH3-only proteins, similar to the multi-domain pro-apoptotic proteins, also 
exist in latent forms, which are modified upon activation. For instance, in the presence of 
apoptotic stimuli, Bad is dephosphorylated at several serine residues leading to its release 
from sequestration by 14-3-3- protein whereas Bid is cleaved to form truncated-Bid 
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(Huang and Strasser, 2000). Such modification of the conformation allows the 
translocation of the BH3-only pro-apoptotic members to the outer mitochondria 
membrane. However, BH3-only proteins function as the initiator of apoptotic pathway 
but require the activation of the Bax family proteins for the induction of apoptosis. Thus 
BH3-only members are likely to trigger apoptosis by using its BH-3 domain to interact 
with either anti-apoptotic Bcl2 proteins (Bcl2 or Bcl-xL) or Bax family proteins (Bax and 
Bak) at the mitochondria membrane, resulting in their suppression or activation 
respectively. BH3-only proteins in the mitochondria can preferentially bind to anti-
apoptotic member such as Bcl2 and Bcl-xL, freeing Bax family proteins to oligomerize, 
leading to cell death. However, it remains controversial if BH3-only proteins can directly 
activate the Bax family (Reed, 2006; Willis and Adams, 2005).  
 
1.5.3   Anti-apoptotic Bcl2 family proteins 
 Anti-apoptotic members of the Bcl2 family can inhibit apoptosis in response to 
most of the cytotoxic insults and they include the founding member Bcl2, Bcl-xL, Bcl-w, 
A1 and Mcl1. The pro-survival proteins contain at least BH1 and BH2 domains whereas 
Bcl2 and its close relatives such as Bcl-xL and Bcl-w contain all four BH domains. Their 
hydrophobic carboxy-terminal domains enable association to the mitochondrial outer 
membrane, endoplasmic reticulum and nuclear membrane. A major role of the pro-
survival Bcl2 proteins is to antagonize their pro-apoptotic counterparts in order to 
maintain mitochondrial membrane integrity and prevent the release of cytochrome C, 
apoptosis-inducing factor (AIF), and certain pro-caspases (Cory and Adams, 2002; 
Strasser et al, 2000).  
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1.5.4   Role of anti-apoptotic Bcl2 family proteins in prostate cancer 
1.5.4.1   Bcl-xL 
 Several studies have linked Bcl-xL to play a cytoprotective role in prostate 
cancer. An earlier report concluded that it was likely that the expression of Bcl-xL 
protein correlated with increasing advanced stages and the presence of metastases in 
adenocarcinoma of the prostate (Krajewski et al, 1994; Castilla et al, 2006). This was 
also reflected in prostate cancer cell lines since Bcl-xL expression was found to be almost 
3-fold higher in androgen-independent PC3 cells than that in androgen-dependent LNCaP 
cells (Liu and Stein, 1997). The level of Bcl-xL could affect the chemosensitivity of 
LNCaP cells to various anti-cancer drugs as it was demonstrated that the overexpression 
of Bcl-xL could increase cell viability when challenged with cytotoxic agents in LNCaP 
and PC3 cells while the down-regulation of Bcl-xL expression increased cell sensitivity 
to cytotoxic agents (Lebedeva et al, 2000).  
 As mentioned earlier, the PI3-K/AKT signaling is one of the major survival 
pathways in LNCaP cell line and its inhibition results in cell death. Interestingly, a study 
suggested that Bcl-xL could mediate a PI3-K/AKT independent survival mechanism in 
LNCaP cells. The overexpression of Bcl-xL protected LNCaP from apoptosis induced by 
inhibition of PI3-K. It was suggested that PC3 resistance to apoptosis induced by 
inhibition of PI3-K could be due to a high Bcl-xL expression since the repression of Bcl-
xL in PC3 cells caused increased sensitivity to inhibition of PI3-K (Yang et al, 2003).  
 Moreover, Bcl-xL was proposed to mediate survival downstream of the AR-
dependent signaling pathway in prostate cancer cell lines. The silencing of AR expression 
by siRNA techniques brought about a drop in Bcl-xL expression as well as an increase in 
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cell death in LNCaP cells while AR silencing-induced apoptosis could be blocked with 
Bcl-xL overexpression (Liao et al, 2005). A recent study reported that Bcl-xL was found 
to interact with pro-apoptotic Bak in LNCaP cells without apoptotic trigger, suggesting 
that Bcl-xL could suppress Bak activity and promote cell survival (Castilla et al, 2006). 
Bcl-xL was reported to affect cell cycle progression where the down-regulation of 
Bcl-xL expression in androgen-independent prostate cancer cell line DU145 led to an 
increase in doubling time while reversion of Bcl-xL expression brought about an increase 
in cell proliferation (Vilenchik et al, 2002). 
  
1.5.4.2   Bcl2 
 Bcl2 has also been proposed to contribute to protection against cell death in 
prostate cancer. The overexpression of Bcl2 allowed for survival of LNCaP cells in 
androgen-deprived condition and conferred resistance to various apoptotic stimuli. Thus 
the elevated expression of Bcl2 was likely to contribute to the development of androgen-
resistance of prostate cancer cells (Raffo et al, 1995).  
Increased Bcl2 expression has been associated with androgen-independent 
progression. It was reported that androgen could directly repress Bcl2 transcription, 
possibly resulting in the up-regulation of Bcl2 expression in androgen-independent 
prostate cancer cells (Bruckheimer et al, 2003). Controversially, another study provided 
evidence that androgen could not directly repress Bcl2 transcription but through 
activation of the retinoblastoma protein and negative modulation of the E2F binding site 
in Bcl2 promoter (Huang et al, 2004).  
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1.6   Objectives of project 
Uncontrolled cellular proliferation and defective regulation of apoptosis can lead 
to tumourigenesis. Tumour cells are able to proliferate even in the absence of growth 
signals. The challenge of cancer therapy is to halt the progression and metastasis of 
tumours and to induce their cellular death.  
Constitutive activation of the PI3-K/AKT signaling pathway in the prostate cancer 
model LNCaP, due to the mutation in its negative regulator PTEN, leads to cell survival 
even in the absence of growth factors. Inhibition of the PI3-K/Akt signaling by treatment 
with PI3-K inhibitor such as LY294002 results in apoptosis, reinforcing the importance 
of PI3-K/Akt activity in LNCaP prostate cancer cells. Clinical trials of PI3-K inhibitors 
are undergoing in an effort to treat cancer. However, it has also been shown that PI3-K 
independent survival mechanisms exists in LNCaP cells which can be induced by growth 
factors (serum), EGF and androgen (Carson et al, 1999; Chao and Clement, 2006). 
Therefore it is crucial to decipher PI3-K independent survival mechanism(s) in order to 
improve the effectiveness of prostate cancer treatment with PI3-K inhibitors. 
For this project, the focus was on PI3-K independent survival pathway mediated 
by androgen. Androgen-dependent LNCaP cells are sensitive to androgen signaling for 
their growth and survival unlike their androgen-independent counterparts. More 
importantly, androgen signaling can induce a survival pathway in LNCaP cells which is 
independent of PI3-K activity but its exact mechanistic action is still obscure. A better 
understanding of androgen-induced survival pathway is vital for the development of more 
effective therapies against prostate tumours. Moreover, in-depth study of the androgen-
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induced survival signaling can shed light on the understanding of the development of 
androgen-independent prostate cancers. 
Therefore, the role of androgen receptor in androgen-induced survival signaling in 
LNCaP cells was first investigated. Besides the androgen-induced signaling, we also 
looked into how androgen could affect the regulators of apoptosis for survival such as the 
Bcl2 family proteins. Interestingly, our results supported the model, whereby activation 
of the AR led to STAT3-induced Bcl-xL up-regulation, which was the key to an increase 
in resistance to apoptosis caused by inhibition of PI3-K in LNCaP cells. 
To understand the development of androgen-independent prostate cancer, we also 
examined survival pathways in a sub-line of LNCaP which has lost its androgen receptor 
expression. Our findings demonstrated the possibility of cross-talk between the two major 
signaling pathways: PI3-K/Akt pathway and MAPK pathway. In addition, a preliminary 
computer-aided model of the survival pathways in LNCaP cell line was designed for the 
simulation study of signaling pathways.  
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2.   MATERIALS AND METHODS 
2.1   Materials 
2.1.1   Cell culture  
Phosphate buffered saline (PBS), heat-inactivated fetal bovine serum (FBS), 
Roswell Park Memorial Institute (RPMI) 1640 media, Dulbecco’s Modified Eagle’s 
Medium (DMEM), trypsin, sodium pyruvate, L-glutamine and charcoal/dextran treated 
fetal bovine serum were purchased from Hyclone, Logan, UT, USA. HEPES and phenol 
red-free RPMI were purchased from Gibco-Invitrogen, MD, USA. Gentamicin sulphate 
was from Cambrex, Walkersville, MD, USA.  
 
2.1.2   Chemicals 
R1881 was purchased from Perkin Elmer, MA, USA. Tumour necrosis factor 
(TNF), wortmannin, propidium iodide (PI), RNase A, epidermal growth factor (EGF), 
cycloheximide, flutamide were supplied by Sigma-Aldrich, St Louis, LO, USA. 
LY294002, AG1478, AKT inhibitor was obtained from Calbiochem, San Diego, CA, 
USA whereas U0126 were obtained from Cell Signaling Technology, Inc., Beverly, MA, 
USA. Caspase-3 substrate Ac-DEVD-AFC was supplied by A.G. Scientific, San Diego, 
CA, USA; caspase 9 substrate Ac-LEHD-AFC was from Bio-rad Laboratories Inc, CA, 
USA. 1X cell lysis buffer was from BD Biosciences Pharmingen, San Jose, CA, USA. 
All siRNA oligonucleotides were chemically synthesized by Qiagen, Inc., Valencia, CA, 
USA. Protein A-agarose beads were bought from Santa Cruz Biotechnology, Inc., CA, 
USA. 
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2.1.3   Antibodies 
Anti-β-actin monoclonal antibody and anti-rabbit FITC conjugate were purchased 
from Sigma-Aldrich, St. Louis, MO, USA. Anti-Phospho-P90RSK (Ser380) antibody, 
anti-Phospho-AKT (Ser473) antibody, anti-AKT antibody, anti-PDK1, anti-Phospho-
ERK1/2 (Thr202/Tyr204) antibody, anti-ERK1/2 antibody, anti-Phospho-MEK1/2 
(Ser217/Ser221) antibody, anti-MEK1/2 antibody, anti-Phospho-Bad (S75) antibody, 
anti-Bad, rabbit polyclonal anti Bcl-xL antibody were from Cell Signaling Technology, 
Inc., Beverly, MA, USA. Anti-RSK1, anti-EGFR, mouse anti-Bad and mouse anti-Bcl-
xL antibody was from Santa Cruz Biotechnology, CA, USA. Anti-androgen receptor 
antibody, anti-Bax-NT, anti-Bak-NT, anti-Cu/Zn SOD, anti-phospho EGFR, anti-
phospho ErbB2 and anti-ErbB2 were purchased from Upstate, Lake Placid, NY, USA. 
Anti-Bcl2 and mouse anti-Bax 6A7 used for flow cytometry were purchased from BD 
Biosciences Pharmingen, San Jose, CA, USA. Anti-VDAC antibody was a generous gift 
from Dr. Catherine Brenner, University of Versailles, France. Horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit immunoglobulin antibody was obtained from 
DakoCytomation, Glostrup, Denmark and HRP-conjugated goat anti-mouse 
immunoglobulin antibody from Pierce Biotechnology, Rockford, IL, USA. Anti-mouse 
FITC conjugate were purchased from Molecular Probes Invitrogen, Eugene, OR.  
 
2.1.4   Plasmids  
pPSA6I-luc was a generous gift from Hetty van der Korput, Department of 
Pathology, Josephine Nefkens Institute, Erasmus Medical Center, The Netherlands. pTA-
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Luc and pNFkB-TA-Luc were purchased from Clontech, CA, USA. pRL-CMV was 
purchased from Promega Corp, Madison, USA. 
 
2.2.   Methods 
2.2.1    Cell culture 
LNCaP-FGC, PC3 and DU145 cells were purchased from the American Type 
Culture Collection (ATCC) and propagated in RPMI-1640 supplemented with 10% FBS, 
2mM glutamine, 1mM sodium pyruvate, 10mM HEPES and 0.05mg/ml gentamicin 
sulfate. All cells were grown at 370C with 5% CO2. LNCaP cells were plated and left for 
2 days in complete medium to promote cell attachment before being subjected to serum 
deprivation or other treatments. The medium of LNCaP cells treated with the synthetic 
androgen R1881 was changed to phenol red-free RPMI-1640 to eliminate endogenous 
hormonal activity as phenol red present in the culture medium has been shown to possess 
significant estrogenic activity (Berthois et al, 1986).  
 
2.2.2    Caspase activity 
After treatment, cells grown in 6-well plate were scraped in medium and collected 
by centrifugation at 2200rpm at 40C for 5 minutes. The cell pellet was washed once with 
PBS and lysed with 50µl of 1X Cell Lysis Buffer (10mM Tris-HCL pH7.5, 10mM 
NaH2PO4/NaHPO4, 130mM NaCl, 1% Triton X-100, 10mM sodium pyrophosphate) for 
10 minutes at 40C. The lysates were subjected to a freeze-thaw step at -200C. The lysates 
were then centrifuged at 3800 rpm for 10 minutes at 40C. 40µl of supernatant was then 
added to an equal volume of 2X caspase reaction buffer (10mM HEPES, pH7.4, 2mM 
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EDTA, 6mM DTT, 10mM KCl and 1.5mM MgCl2) supplemented with protease 
inhibitors (1mM PMSF, 10µg/ml aprotinin, 20µg/ml pepstatin A, 10µg/ml leupeptin). 
The reaction mixture was added to 50µM of specific caspase substrates (caspase 3 
substrate: Ac-DEVD-AFC or caspase 9 substrate: Ac-LEHD-AFC) and incubated at 370C 
for 1 hour. Fluorescence was read at excitation 400nm and emission 505nm using 
Spectrafluoro Plus spectrophotometer (Tecan, GmbH, Grödig, Austria). Caspase activity 
was calculated as relative fluorescence unit (RFU) per amount of protein (µg). 
 
2.2.3    Sub-G1 population determination  
Cells were plated in 6-well plates and treated accordingly. Cells were collected by 
scraping in medium and washed with chilled 1X PBS containing 1% FBS. The cells were 
resuspended, fixed with 70% ethanol and incubated for at least 30 minutes at 4oC. After 
fixation, the cells were washed once with PBS + 1% FBS and incubated in staining 
solution (10µg/ml PI, 250µg/ml RNase A in PBS + 1% FBS) for 30 minutes at 370C. The 
samples were then filtered through a 41µm pore size filter and cell cycle profile of 20 000 
cells was analyzed by flow cytometry (Beckman Coulter Epics Altra, San Diego, CA 
USA) with excitation at 488nm and emission at 610nm. Data were analyzed with 
WinMDI Version 2.8 software. Apoptotic population was determined by the percentage 
of cells in sub-G1 phase. 
 
2.2.4    RNA interference 
All 21-nucleotide siRNAs were chemically synthesized by Qiagen-Xeragon, 
Valencia, CA, USA. Specified concentration of siRNA (refer to Table 1) was used to 
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silence the gene of interest using CalPhosTM Mammalian transfection kit (Clontech, CA, 
USA) as recommended in the manufacturer’s protocol. The inverted luciferase gene 
sequence was used as a negative control (Co siRNA) for gene silencing. Briefly, cells at 
approximately 50% confluency were transfected with 50-100nM of specific siRNA. The 
cell culture medium was changed to fresh DMEM supplemented with 10% FBS prior to 
transfection. The siRNA was mixed with an appropriate amount of 2M calcium 
phosphate solution and sterile water. The mixture was then added to an equal volume of 
2x HBS while vortexing. The transfection reaction mixture was incubated at room 
temperature for 20 minutes before adding dropwise to the cells. The medium was 
changed to fresh regular culture medium the following day. The cells were subsequently 
subjected to serum deprivation or various treatments at 48 hours post-transfection and 
efficiency of gene silencing was determined by western blot analysis.  
 
Table 1. siRNA sequences of various target genes  
Gene  siRNA sequence 
(5’Æ3’) 
Concentration of 
siRNA (nM) used 
Control UUC UCC GAA CGU GUC ACG UdTdT 
ACG UGA CAC GUU CGG AGA AdTdT 
50 
AKT UGC CCU UCU ACA ACC AGG AdTdT 
UCC UGG UUG UAG AAG GGC AdTdT 
50 
Bak UGA GUA CUU CAC CAA GAU U dTdT 
AAU CUU GGU GAA GUA CUC A dTdT 
100 
Bax GGU GCC GGA ACU GAU CAG A dTdT 
UCU GAU CAG  UUC CGG CAC C dTdT 
50 
Bcl-xL CAG GGA CAG CAU AUC AGA GdTdT 
CUC UGA UAU GCU GUC CCU GdTdT 
50 
EGFR CUC UGG AGG AAA AGA AAG UdTdT 
ACU UUC UUU UCC UCC AGA GdTdT 
50 
PDK1 GAG ACC UCG UGG AGA AAC UdTdT 
AGU UUC UCC ACG AGG UCU CdTdT 
50 
STAT3  CAU CUG CCU AGA UCG GCU AdTdT 
UAG CCG AUC UAG GCA GAU GdTdT 
50 
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2.2.5    Bax/Bak activation assay 
Cells were scraped in medium on ice and centrifuged 2500rpm at 40C for 5min. 
The cell pellet was washed once with 1X PBS, fixed with 0.5% paraformaldehyde and 
left on ice for 30min. The cells were then washed with PBS containing 1% FBS twice 
and incubated with anti-Bax NT (BD Pharmigen) or anti-Bak NT (Upstate) in staining 
buffer (1X PBS, 1% FBS, 0.1% saponin) for 1h at room temperature. Anti-Bax NT 
recognized the amino acid 12-24 of Bax whereas anti-Bak NT recognized the amino acid 
23-38 which are exposed when Bax and Bak undergo a conformational change upon 
activation. The samples were washed twice with staining buffer followed by incubation 
with goat anti-mouse or goat anti-rabbit antibody conjugated to FITC in staining buffer at 
room temperature for 45 minutes. The samples were again washed twice with PBS 
containing 1% FBS and resuspended in 500µl of PBS. Cells treated with 4µM 
staurosporine were used as positive control for Bak and Bax activation and samples not 
incubated with the primary antibody were used as negative control. The samples were 
then filtered through a 41µm pore size filter and 30000 cells were analyzed by flow 
cytometry (Beckman Coulter Epics Altra, San Diego, CA USA). Data were analyzed 
with WinMDI Version 2.8 software. 
 
2.2.6    Dual luciferase assay 
 Cells plated in 6-well plate were co-transfected with the 3.5µg of the respective 
Luciferase reporter plasmid and 0.5µg of Renilla luciferase reporter plasmid pRL-CMV 
according to the manufacturer’s protocol from the CalPhosTM Mammalian transfection 
kit. After transfection and respective treatment, the reporter gene assay was carried out as 
 Materials and methods 27
recommended in the protocol of the Dual Luciferase assay system kit (Promega Corp, 
Madison, USA). Briefly, the cells were lysed with 200µl of 1X Passive Lysis Buffer and 
subjected to a freeze-thaw cycle. The cell lysate was centrifuged at maximum speed and 
the supernatant was collected. 20µl of the supernatant was mixed with 100µl of 
Luciferase assay reagent II (LARII) and the luminescence reading for 10seconds was 
taken with the Turner Design 20/20 Luminometer (Sunnyvale, CA, USA). 100µl of Stop 
& Glo Reagent was added to the same tube and the Renilla luciferase reading was taken. 
The relative luminescence reading (RLU) of luciferase was normalized to Renilla reading 
for internal control and normalized to protein amount. 
 
2.2.7    Western blot 
Cells were grown on 60mm tissue culture dish and after the respective treatments 
the cells were washed once and scraped in PBS. The cells were centrifuged at 2200rpm 
for 5 minutes at 40C and the cell pellet was lysed with 1X RIPA lysis (10mM Tris-HCL 
pH7.4, 30mM NaCl, 1mM EDTA) with 1% Nonidet P-40 and supplemented with 
protease inhibitors (1mM phenylmethylsulfonylfluoride (PMSF), 1µg/ml of leupeptin, 
pepstatin and aproptonin each) and 1mM of sodium orthovanadate for 30 minutes on ice. 
Lysates were centrifuged at maximum speed for 10min and protein concentration of the 
supernatant was determined using the Coomassie plus protein assay reagent (Pierce, 
Rockford, IL, USA). Approximately 70µg of protein was mixed with SDS-loading buffer 
and heated at 950C for 5 minutes. Samples were separated on 7.5-12% polyacrylamide 
gel and transferred on to nitrocellulose membrane. The membrane was blocked with 
blocking buffer (5% non-fat milk in Tris-buffered saline and 0.1% Tween 20 (TBST)) for 
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1 hour, washed with TBST thrice and subsequently incubated with primary antibody 
overnight. The membrane was washed with TBST thrice and incubated with secondary 
antibody labeled with horse radish peroxidase (HRP) for 1 hour. Chemiluminescence was 
detected using Supersignal chemiluminescent substrate (Pierce, Rockford, IL, USA). In 
experiments requiring the detection of phosphorylated proteins, the membrane was 
subsequently stripped with Restore Western stripping buffer (Pierce, Rockford, IL, USA) 
and reprobed for the total protein. Detection of β-actin was performed to check for equal 
protein loading. Densitometry analysis of image obtained was performed by Multi Gauge 
V3.0 software (Fuji Film, Japan).  
 
2.2.8    Purification of nucleus 
Isolation of the nucleus was performed with NE-PER Nuclear and cytoplasmic 
extraction reagent kit (Pierce Biotechnology, Rockford, IL, US) and according to the 
manufacturer’s protocol. Cells plated in 100mm dish were treated and isolated by 
scraping. The cell pellet was washed once with PBS and lysed with 200µl of cytoplasmic 
extraction reagent I for 10 minutes. 11µl of cytoplasmic extraction reagent II was then 
added, vortexed and incubated on ice for 1 minute. Next the samples were centrifuged at 
16000g for 5 minutes at 4oC. The supernatant contained the cytoplasmic extract while the 
pellet was re-suspended in 100µl of nuclear extraction reagent and incubated on ice for 
40 minutes with vortexing every 10 minutes. The samples were centrifuged for 10 
minutes at 16000g at 40C. The supernatant contained the nuclear extract. To determine 
the translocation of proteins to the nucleus, the isolated nuclear and cytoplasmic fractions 
were separated on a 7.5% polyacrylamide gel and subjected to Western blot. Detection of 
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the nuclear marker PARP was performed to show the purity of the nuclear and 
cytoplasmic fractions. 
 
2.2.9    Purification of mitochondria  
LNCaP cells were plated on 100mm dish and treated for 1½ hour. The cells were 
then collected by scraping in 1X PBS. The cells were centrifuged at 600g for 5 minute at 
40C and the cell pellet was washed once with 1X PBS. The cell pellet was then 
resuspended in 500µl of extraction buffer (200mM mannitol, 68mM sucrose, 50mM 
Pipes-KOH pH7.4, 50mM KCl, 5mM EGTA, 2mM MgCl2, 1mM DTT) supplemented 
with protease inhibitor (1mM PMSF, 10µg/ml aproptonin, 20mg/ml pepstatin A, 
10mg/ml of leupeptin) and incubated on ice for 20 minutes. The cells were homogenized 
using the Dounce homogenizer with 35 strokes and the lysate was centrifuged at 700g for 
10 minutes at 40C to remove nuclei and unlysed cells. The supernatant was further 
centrifuged at 10000g for 30 minutes at 40C. The pellet contained the intact mitochondria 
whereas the supernatant contained the cytosolic fraction. The mitochondria pellet was 
further purified by washing it once with the extraction buffer and centrifuged at 10000g 
for 10 minutes. The cytosolic fraction was centrifuged at 16000g for 10 minutes to 
remove any residual mitochondria. Both purified fractions were incubated with 0.5% 
Triton X-100 in extraction buffer for 15 minutes on ice. Approximately 30µg of protein 
from both fractions was separated on a 12% polyacrylamide gels and immunoblotted for 
the various Bcl2 family proteins. Purity of the mitochondria and cytosolic fraction was 
assessed by determining the localization of mitochondrial and cytosolic markers, VDAC 
and Cu/Zn SOD, respectively. 
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2.2.10   Immunoprecipitation 
Total cell lysates or lysates subjected to subcellular fractionations were collected 
after various treatments. Protein concentration was determined with Coomasie plus 
protein assay reagent (Pierce, Rockford, IL, USA) and approximately 300µg of protein 
from total cell lysate or 80µg of protein from mitochondria fractions was incubated with 
the respective primary antibody first overnight at 40C followed by incubation with 20µl 
of protein A-agarose beads at 40C for another 3 hours. The beads were pelleted down by 
centrifuging at 1500 rpm and the supernatant was removed. The beads were then washed 
thrice with extraction buffer containing 0.5% Triton X-100 to remove unbound proteins. 
20µl of 3X SDS sample loading buffer was added to the beads and the samples were then 
heated at 950C for 5 minutes. The samples were then used for Western blot to detect for 
co-immunoprecipitated proteins. 
 
2.2.11   Statistical analysis 
 Statistical analysis was performed using unpaired Student’s t-test and with p-
value < 0.05 to be considered as statistically significant.  
 
 Results 31
3.   RESULTS 
3.1   PI3-K independent survival pathway in LNCaP 
3.1.1   Androgen mediates PI3-K independent survival 
PI3-K independent survival pathways exist in LNCaP cells which can be 
mediated by serum, EGF and androgen (Carson et al, 1999). It has been found that serum 
mediated cell survival in the presence of LY294002 by inhibiting the translocation of Bad 
and Bax to the mitochondria whereas EGF maintained the phosphorylation of MEK, 
ERK and p90rsk which in turn maintained the phosphorylation of Bad, thereby 
preventing cell death (Chao and Clement, 2006). This project will focus on the 
mechanism of androgen-mediated PI3-K independent survival. 
 LNCaP cells were grown to 70% confluency and serum deprived in phenol red-
free RPMI for 24 hours. Phenol red-free RPMI was used in all experiments involving 
treatment with androgen due to the interference of phenol red as its structure resembled 
hormones such as estrogen and possessed weak estrogenic activity (Berthois et al, 1986). 
The cells were then incubated with 25µM LY294002, a PI3-K inhibitor, together with 
5nM R1881 (synthetic androgen), 100ng/ml EGF or 10% charcoal-stripped serum (cs). 
Charcoal-stripped serum was used to minimize endogenous hormones present in the 
serum. Apoptosis was then assessed by caspase 3 activity after 9 and 24 hours of 
treatment. Both serum and EGF were able to decrease the caspase 3 activity induced by 
LY294002 (Figure 1), indicating that serum and EGF could rescue LNCaP cells from 
apoptosis even when PI3-K was inhibited. Charcoal-stripped serum was used to show 
that the rescue of cell death by serum was not due to the effect of hormones. However, 
treatment with R1881 did not show a significant rescue in the caspase 3 activity induced 
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by LY294002. As mentioned above, the mechanism by which serum and EGF rescue cell 
death induced by inhibition of PI3-K involved phosphorylation of proteins rather than 
synthesis of proteins, therefore the inhibition of cell death was rapid. It could be possible 
that androgen require a longer period of incubation to mediate the rescue in cell death so 
no rescue of caspase 3 activity in the presence of combined R1881 and LY294002 































Figure 1. Serum and EGF but not androgen rescue LNCaP cells from apoptosis 
induced by inhibition of PI3-K. LNCaP cells were first serum deprived in phenol red-
free RPMI medium for 24h and subsequently incubated with 25µM of LY294002 (LY) in 
the presence or absence (ns) of 10% charcoal-stripped serum (cs), 100ng/ml EGF (EGF) 
or 5nM R1881 (R1881) for 9 and 24 hours. Cell death was assessed by caspase 3 activity 
as described in Materials and Methods. Results are shown as mean ± S.E (standard error) 




To find out if androgen could rescue cells from apoptosis induced by inhibition of 
PI3-K with a longer period of exposure, LNCaP cells were serum deprived in phenol red-
free RPMI and pre-treated with 5nM R1881 for 24 hours before being exposed to 25µM 
LY294002 in the presence of 5nM R1881 for 9 and 24 hours. Cell death was measured 
by caspase 3 activity and caspase 9 activity (Figure 2A and 2B). Pre-treatment of LNCaP 
cells with 5nM R1881 for 24 hour enabled androgen to significantly decrease both 
caspase 3 and 9 activities induced by LY294002. This indicated that the mechanism by 
which androgen inhibited cell death induced by LY294002 could likely involve the 
synthesis of new proteins. 
To confirm that the cell survival mediated by R1881 requires the expression of 
androgen receptor, a subline of the LNCaP which did not express the androgen receptor 
(AR-negative LNCaP) was used. Results showed that even with 24 hour pre-treatment 
with androgen, there was no detectable level of androgen receptor in AR-negative 
LNCaP cells while, as expected, there was clearly an increase in the androgen receptor 
expression induced by androgen in the LNCaP cells (Figure 3A). Furthermore, our results 
showed that, in the absence of androgen receptor, androgen was unable to decrease 
caspase 3 activity (Figure 3B) and sub G1 population (Figure 3C) caused by an inhibition 
of PI3-K with LY294002. This effect was not due to any defect in the AR-negative 
LNCaP since charcoal-stripped serum was still able to rescue cell death in the presence of 
LY294002, indicating that PI3-K independent survival of AR-negative LNCaP cells 
mediated by serum was not impaired. Thus the PI3-K independent cell survival mediated 







































































  9h 24h
 
Figure 2.  Pre-treatment of LNCaP cells to androgen for 24 hours was able to rescue 
LNCaP cells from apoptosis induced by inhibition of PI3-K. LNCaP cells were serum 
deprived in phenol red-free RPMI medium and pre-treated with 5nM of R1881 for 24 
hours before being incubated with serum-free medium (ns), 25µM LY294002 (LY) and 
5nM R1881 for 9 and 24 hours. A) Caspase 3 and B) capase 9 activity were assessed as 
described in Materials and Methods. Results are shown as mean ± S.E of three 
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Figure 3. Expression of androgen receptor is required for androgen to rescue 
LNCaP cells from apoptosis induced by inhibition of PI3-K. A) wild-type LNCaP 
cells and AR-negative LNCaP cells were serum deprived in phenol red-free RPMI 
medium and pre-treated with 5nM R1881 for 24h followed by incubation with 25µM 
LY294002 and 5nM R1881 for 1 hour. The expression of AR was determined by 
Western blot as described in Material and Methods and shown as a representative blot out 
of at least three independent experiments. B) AR-negative LNCaP cells were serum 
deprived or pre-treated with 5nM R1881 for 24 hours before being incubated with 25µM 
LY294002 in the presence or absence (ns) of 10% charcoal-stripped serum (cs) and 5nM 
R1881. Apoptosis was assessed by B) caspase 3 activity after 9 hours and 24 hours of 
treatment C) sub G1 population after 24 hours of treatment as described in Materials and 
Methods. Results were shown as mean ± S.E of three independent experiments done in 























































Since the expression of androgen receptor is important for androgen mediated cell 
survival, next we assessed if the activity of the androgen receptor was involved in the 
survival pathway mediated by androgen. The anti-androgen, flutamide, competitively 
binds to androgen receptor and blocks the dimerization of androgen receptor or the 
binding of androgen receptor to DNA. The ability of flutamide to block androgen 
receptor activity in LNCaP cells was confirmed by determining the promoter activity of 
prostate specific antigen (PSA), a downstream target of the activated androgen receptor. 
Dual Luciferase assay was assessed in LNCaP cells transfected with the empty vector 
pTA-luc or the reporter plasmid pPSA6I-luc, which contains the PSA promoter inserted 
5’ to the luciferase gene. Treatment with flutamide decreased the PSA promoter activity 
induced by androgen (Figure 4A), indicating that 10µM of flutamide could effectively 
inhibit AR activity. Treatment with charcoal-stripped serum served as a negative control 
for androgen receptor activity.  
After 9 hours of treatment, flutamide clearly abolished the androgen-mediated 
decrease in apoptosis caused by LY294002 as seen from the caspase 3 activity and sub 
G1 population (Figure 4B and C respectively). After 24 hours of treatment, flutamide was 
still able to block the androgen-mediated decrease in caspase 3 activity. Though 
flutamide did not significantly block the androgen-mediated decrease in sub G1 
population at 24 hours, the sub-G1 population of cells treated with androgen and 
LY294002 was still significantly higher in the presence of flutamide compared to that in 
the absence of flutamide. Thus the androgen-mediated PI3-K independent survival 
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Figure 4. Activity of androgen receptor is required for androgen-mediated PI3-K 
independent survival. A) LNCaP cells were co-transfected with pPSA-luc or the empty 
vector pTA-luc together with pRL-CMV and 48 hours post-transfection the cells were 
serum deprived in phenol red-free RPMI medium and incubated with 5nM R1881 and 
10µM flutamide for 8 and 24 hours. PSA promoter activity was determined by the dual 
luciferase assay and PSA promoter activity was normalized with protein content as 
described in Materials and Methods. B) LNCaP cells were serum deprived or pre-treated 
with 5nM R1881 and 10µM flutamide for 24 hours in phenol red-free RPMI medium. 
The cells were then exposed to 25µM LY294002 and 5nM R1881 in the absence or 
presence of 10µM flutamide for 9 hours and 24 hours. Cell death was measured by 
determining caspase 3 activity and C) sub G1 population. All results are shown as mean ± 


















3.1.2   MAPK pathway is not involved in androgen-mediated survival 
Androgen receptor when bound to androgen becomes activated and translocates to 
the nucleus to function as a transcription factor and regulates a number of genes. PI3-K 
independent survival pathways brought about by serum and EGF has been investigated 
(Chao and Clement, 2006). EGF maintained the activation of the MEK/ERK/RSK 
module which prevents Bad dephosphorylation in the presence of LY294002. Here we 
wanted to test if androgen mediated survival by a similar mechanism. Incubation of 
LNCaP cells with R1881 did not activate MEK/ERK/RSK1 module since phosphorylated 
form of MEK, ERK and RSK were not detected, however EGF clearly induced the 
phosphorylation of MEK (Figure 6), ERK and RSK (Figure 5). The androgen receptor 
expression confirmed that the LNCaP cells were responsive to androgen.  
In the presence of LY294002, Bad was dephosphorylated at serine 75 (S75) and 
androgen could not maintain the phosphorylation of Bad, unlike the strong Bad 
phosphorylation maintained by EGF, possibly due to the activation of MEK/ERK/RSK 
module (Figure 6).  
The phosphorylation of AKT at S473 was detected to show the inhibition of AKT 
activation by LY294002. Inhibition of PI3-K activity by LY294002 could probably block 
AKT phosphorylation at S473 either by preventing PDK1 to phosphorylate AKT at 
Threonine 308 (T308), which might prevent the subsequent phosphorylation of AKT 
S473 by other kinase, or by directly inhibiting the kinase for AKT S473 such as rictor-
mTOR complex. Phosphorylated AKT at T308 was not shown as its level was too low for 
successful detection by Western blot. Previous data from our laboratory has already 
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verified that LY294002 could inhibit phosphorylation of AKT at Threonine 308 in 
LNCaP by immunoprecipitation.   
To reaffirm that the MAPK pathway was not involved in androgen-mediated PI3-
K independent survival in LNCaP cells, we determined if LY294002-induced apoptosis 
could be prevented by androgen when ERK activation was blocked by a specific MEK 
inhibitor U0126. From the caspase 3 activity, androgen could still block apoptosis in the 
presence of U0126 and this was not due to inefficient inhibition of MAPK pathway by 
U0126 since U0126 could significantly block EGF-mediated survival (Figure 7A). 
Moreover, Western blot analysis also showed that U0126 could decrease the level of 
phosphorylated ERK induced by EGF (Figure 7B).  
Hence, we showed that androgen was able to protect LNCaP cells from apoptosis 
caused by inhibition of the PI3-K/AKT pathway and this protection was not brought 
about by activation of MAPK, another major survival pathway. The level of 
phosphorylated Bad did not seem to be important for androgen-mediated survival, unlike 
for EGF-mediated survival, since the latter was abolished with dephosphorylation of Bad 









































Figure 5. Androgen did not activate the ERK/p90rsk pathway. LNCaP cells were 
serum deprived or pre-treated with 5nM R1881 for 24 hours in phenol red-free RPMI. 
Cell lysates were collected (0h) or the cells were incubated with 10% charcoal-stripped 
serum (cs), 100ng/ml EGF (EGF) or 5nM R1881 (R1881) for another 1 hour before cell 
lysates were collected. The expression of various proteins was determined by Western 
blot as described in Materials and Methods. Expression of β-actin was shown for loading 


























































Figure 6. Androgen blocked cell death caused by inhibition of PI3-K by a 
mechanism different from serum and EGF. LNCaP cells were serum deprived or pre-
treated with 5nM R1881 for 24 hours in phenol red-free RPMI. Cell lysates were 
incubated with 10% cs-FBS (cs), 100ng/ml EGF (EGF) or 5nM R1881 (R1881) in the 
presence or absence of 25µM LY294002 (LY) for 1 hour before cell lysates were 
collected. The expression of various proteins was determined by Western blot as 
described in Materials and Methods. Expression of β-actin was shown for loading 

















































            
            
            
            
            
            
            
          
 




Figure 7. Androgen mediated survival is independent of MAPK activity. A) LNCaP 
cells were serum deprived or pre-treated with 5nM R1881 for 24 hours in phenol red-free 
RPMI. The cells were then pre-treated with or without 10µM U0126 for 3 hours before 
incubated with 25µM LY294002 (LY) in the presence or absence of 100ng/ml EGF or 
5nM R1881 for another 3 hours. Apoptosis was determined by caspase 3 activity and 
shown as mean ± S.E. from two independent experiments done in duplicates. B) LNCaP 
cells were serum deprived or pre-treated with 5nM R1881 for 24 hours in phenol red-free 
RPMI. The cells were then pre-treated with or without 10µM U0126 for 3 hours before 
incubated with 100ng/ml EGF or 5nM R1881 for another 3 hours. Phosphorylation form 
of ERK and Bad were determined by Western blot as described in Materials and Methods 
and expression of β-actin was shown for loading control. Result was shown as a 























































3.1.3   Role of Bcl-xL in androgen-mediated survival 
Androgen could mediate PI3-K and MAPK independent survival in the absence 
of growth factors and this did not depend on the phosphorylation of Bad. Next we wanted 
to find out which proteins were responsible for the resistance to apoptosis. This could 
likely be due to regulation of protein expression since cell were required to be exposed to 
R1881 for 24-hour prior to incubation with LY294002 for its resistance to cell death. 
 Several reports have shown that Bcl-xL and Bcl2 are important for LNCaP 
survival (Lebedeva et al, 2000; Raffo et al, 1995). First we investigated the expression of 
the Bcl2 family members Bcl-xL and Bcl2. Androgen induced the anti-apoptotic protein 
Bcl-xL expression in LNCaP cells but, interestingly it repressed another anti-apoptotic 
protein Bcl2 expression (Figure 8A). This effect of androgen on Bcl-xL and Bcl2 
expression was more pronounced after 8 hours of treatment than after 1 hour. This was 
observed even in the presence of LY294002, indicating that it did not involve the PI3-
K/AKT pathway. Androgen could not induce Bcl-xL expression and repress Bcl2 
expression in androgen receptor-negative LNCaP cells (Figure 8B) nor in the presence of 
anti-androgen flutamide (Figure 8C). These data indicated that the changes in Bcl-xL and 
Bcl2 expression levels were likely to involve the androgen receptor activity as a 
transcription factor. Furthermore, cycloheximide, which blocks protein synthesis, 
abolished the induction of Bcl-xL protein expression by androgen (Figure 9). This 
indicated that androgen probably increased Bcl-xL protein expression by an increase in 
transcription rather than maintaining the stability of Bcl-xL protein.  
 Androgen-sensitive prostate cancer can advance into an androgen-independent 
stage that is more resistant to chemotherapeutic agents. PC3 and DU145 cell lines are the 
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common androgen-independent prostate cancer models. We compared the expression of 
Bcl-xL and Bcl2 in LNCaP, PC3 and DU145 cells. It was observed that the high Bcl-xL 
and low Bcl2 expression in R1881-treated LNCaP cells resembled the high Bcl-xL to 
Bcl2 ratio found in androgen-independent PC3 and DU145 cells (Figure 10). The high 
Bcl-xL expression in PC3 and DU145 could probably explain the higher resistance of 
these cells to cell death and, as expected, Bcl-xL and Bcl2 expression in androgen-
independent PC3 and DU145 cells were unaffected in the presence of androgen. 
Therefore, androgen-induced Bcl-xL expression in LNCaP could likely be responsible for 
conferring increased cell resistance to apoptotic triggers such as inhibition of PI3-K by 
LY294002.  
 Apoptosis is regulated by the fine balance between pro-apoptotic (e.g Bcl2 and 
Bcl-xL) and anti-apoptotic members (Bax and Bak) of the Bcl2 family proteins. 
Androgen induced anti-apoptotic Bcl-xL expression in LNCaP cells and, in addition, 
repressed another major anti-apoptotic protein Bcl2. The repression of a major anti-
apoptotic member of Bcl2 family could probably cause Bcl-xL to play a more critical role 
in protecting LNCaP cells against apoptosis. 
 To determine if Bcl-xL plays a role in androgen mediated PI3-K independent 
survival, siRNA specific for Bcl-xL was transfected into LNCaP cells and cell death was 
assessed after the cells were treated with androgen and LY294002. The inhibition of 
LY294002-induced caspase 3 activity (Figure 11B and D) and sub G1 population (Figure 
11C and E) mediated by androgen were significantly abolished when Bcl-xL expression 
was repressed by siRNA transfection. Thus Bcl-xL was critical in androgen mediated 





































Figure 8. Androgen induces the expression of Bcl-xL but represses the expression of 
Bcl2. A) LNCaP cells were serum deprived or pre-treated with 5nM R1881 for 24 hours 
in phenol red-free RPMI before incubated with 25µM LY294002 (LY) or/and 5nM 
R1881 for 1 and 8 hours. B) AR-negative LNCaP cells were also subjected to the same 
treatment as in (A). C) LNCaP cells were serum deprived and pre-treated for 24 hours 
with 5nM R1881 in phenol red-free RPMI in the presence of absence of 10µM flutamide 
before being incubated with 25µM LY294002 and 5nM R1881 for 8 hours. Cell lysates 
were collected after all the above treatments and the expression of Bcl-xL and Bcl2 
proteins were determined by Western blot as described in Materials and Methods. β-actin 
was shown for loading control and all results shown are representative blots out of at 
least three independent experiments. 
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Figure 9. Increase in Bcl-xL expression caused by androgen is not due an increase in 
the stability of Bcl-xL protein. LNCaP cells were serum deprived and treated with 5nM 
R1881 (R) and 10µg/ml cycloheximide (C) in phenol red-free RPMI for 8 and 24 hours. 
Cell lysates were collected for Western blot to determine the expression of Bcl-xL. β-
actin was shown for loading control. Result was shown as a representative blot out of 
















































Figure 10. Ratio of Bcl-xL/Bcl2 protein in androgen-treated LNCaP cells resembled 
that of androgen-independent prostate cancer models. A) LNCaP, PC3 and DU145 
cells were serum deprived or pre-treated with 5nM R1881in phenol red-free RPMI for 24 
hours before incubated with 25µM LY294002 (LY) and 5nM R1881 for 1 and 8 hours. 
Bcl-xL and Bcl2 protein expression was determined by Western blot and β-actin was 
shown for loading control. Result shown was a representative blot out of three 
independent experiments. B) Comparision of Bcl-xL and Bcl2 expression in LNCaP, PC3 
and DU145 cells by densitometry analysis of (A). Relative intensity of bands were 
normalized to β-actin and expressed as percentage of control (LNCaP cells in medium). 
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Figure 11. Bcl-xL is involved in androgen-mediated PI3-K independent survival. 
LNCaP cells were transfected with 50nM of control (co si) or Bcl-xL (Bcl-xL si) siRNA. 
48 hours post-transfection, the cells were serum deprived or pre-treated with 5nM R1881 
for 24 hours in phenol red-free RPMI followed by a treatment with 25µM LY294002 and 
5nM R1881 for 9 and 24 hours. A) Efficiency of Bcl-xL repression was determined by 
Western blot and shown as a representative blot out of six independent experiments. Cells 
death was measured by B) caspase 3 activity and C) sub G1 population determination by 
PI staining. Results were shown as mean ± S.E. from three independent experiments done 
in duplicates. (D and E) Results in (B) and (C) respectively were calculated as percentage 
of decrease of LY-induced cell death in androgen-treated cells over cells in medium and 
shown as mean ± S.E. from three independent experiments done in duplicates. * p<0.01 
 Results 50
3.1.4   Up-regulation of Bcl-xL upon androgen treatment did not involve NFκB 
Bcl-xL may be involved in androgen-mediated survival but the mechanism which 
androgen regulates Bcl-xL expression is not yet clearly understood. NFκB has also been 
shown to regulate Bcl-xL and other survival proteins (Chen et al, 2000). Hence we 
wanted to find out if androgen could activate NFκB, which could play a role in the up-
regulation of Bcl-xL. LNCaP cells were transfected with pNFκB-TA-Luc, which 
contained four tandem copies of the NFκB consensus sequence located up-stream of the 
TA promoter and luciferase gene, and treated with androgen. R1881 was unable to induce 
significant NFκB activity even after 24 hours of exposure (Figure 12). 40ng/ml of tumour 
necrosis factor (TNF)-treated cells were used as a positive control. Therefore androgen-






























Figure 12. Androgen did not induce NFκB activity. LNCaP cells were co-transfected 
with pNFκB-TA-Luc and pRL-CMV and 48 hours post-transfection the cells were 
incubated with 5nM R1881 or 40ng/ml of TNF in phenol red-free RPMI medium for 8 
and 24 hours. NFκB activity was assessed by dual luciferase reporter assay as described 
in Materials and Methods. Results were shown as mean ± S.E. from three independent 
experiments done in duplicates. 
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3.1.5   Role of STAT3 in androgen-mediated survival  
Besides NFκB, Bcl-xL gene expression has been shown to be regulated by 
STAT3 (Sevilla et al, 2001). Thus we hypothesized that androgen could increase Bcl-xL 
expression by acting through STAT3. To find out if androgen-induced Bcl-xL expression 
is dependent on STAT3, STAT3 gene expression was silenced by siRNA transfection in 
LNCaP cells and Bcl-xL expression was determined by Western blot. STAT3 repression 
did not affect the basal Bcl-xL expression but it prevented androgen-induced increase in 
Bcl-xL protein (Figure 13). This indicated that STAT3 expression could be critical for 
androgen-induced up-regulation of Bcl-xL to promote cell survival in LNCaP cells. 
 We next assessed how androgen could affect STAT3 to mediate cell survival. 
STAT3 when phosphorylated at Tyr 705 and Ser 727 becomes activated and dimerizes 
via SH2 domains. STAT3 dimers translocate into the nucleus and regulate its target 
genes. Western blot analysis was performed on androgen-treated LNCaP cells to 
determine STAT3 activation and expression. An increase in STAT3 expression and its 
phosphorylation at both residues Tyr705 and Ser727 were observed in LNCaP cells 
incubated with R1881 (Figure 14A) and these could be blocked by the addition of protein 
synthesis inhibitor cycloheximide (Figure 14B). This implied that androgen-induced 
expression and phosphorylation of STAT3 required protein synthesis and was not a 
function of enhanced stability of the protein. We observed that flutamide reduced R1881-
induced STAT3 phosphorylation (Figure 14C) albeit by approximately 20% (based on 
densitometric ananlysis). Thus the increase in STAT3 phosphorylation observed in the 
presence of androgen could probably be due to an increase in STAT3 protein induced by 
androgen and allowing the kinase to phosphorylate more STAT3. Androgen-induced 
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STAT3 phosphorylation and expression was independent of PI3-K pathway and likely a 
downstream effect of the androgen receptor since they could be blocked by the anti-
androgen flutamide. 
In addition, the increase in STAT3 by androgen was observed in both the 
cytosolic and nuclear pool. Androgen also increases cytosolic and nuclear phosphorylated 
STAT3 Tyr705 and Ser727 respectively (Figure 14D). These were observed when PI3-K 
pathway was inhibited by LY294002. These data indicate that probably androgen activate 
the androgen receptor (increase in androgen receptor nuclear translocation in Figure 
14D), which in turn could increase STAT3 expression, leading to an increase in its 
phosphorylation and consequently an increase in STAT3 nuclear translocation. This 
could then up-regulate the expression of Bcl-xL which confered PI3-K independent 
survival in LNCaP.  
R1881-induced phosphorylation of STAT3 at Ser727 was observed mainly in the 
nucleus and this could likely be due to phosphorylation of STAT3 at Ser727 was to 
enhance the transcriptional activity of phospho-STAT3 Tyr705 that has translocated into 
the nucleus (Wen et al, 1995). Basal levels of phosphorylated STAT3 found in nuclear or 
cytoplasmic fractions of unstimulated cells (cells in medium) could probably be due to 
the continuous nucleocytoplasmic shuttling of STAT3 (Pranada et al, 2004).  
 To further illustrate the role of STAT3 in androgen-mediated cell survival, cell 
death induced by inhibition of PI3-K/Akt signaling was assessed in STAT3-repressed 
LNCaP cells. The repression of STAT3 abolished androgen-mediated inhibition of 
LY294002-induced caspase 3 activity (Figure 15B and D) and sub G1 population (Figure 
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Figure 13. Androgen requires STAT3 to increase Bcl-xL expression. LNCaP cells 
were transfected with control (co si) or STAT3 siRNA (STAT3 si). 48 hours post-
transfection, the cells were incubated with 5nM R1881 for 24 hours in serum-free phenol 
red-free RPMI medium. A) STAT3 and Bcl-xL expression was determined by Western 
blot and β-actin was shown for loading control. Result shown was a representative blot 
out of three experiments. B) Densitometric analysis on results shown in (A) and 
calculated as percentage of control and expressed as mean ± S.D from three independent 
experiments. * p<0.01  
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Figure 14. Androgen induces STAT3 phosphorylation, expression and nuclear 
translocation. A) LNCaP cells were serum deprived and pre-treated with 5nM R1881 in 
phenol red-free RPMI for 24 hour before being incubated with 25µM LY294002 (LY) 
and 5nM R1881 for 1 hour. Western blot was performed to detect for phosphorylated 
STAT3 and total STAT3 expression as described in Materials and Methods. 
Representative densitometry analysis normalized to β-actin and calculated as percentage 
of control (LNCaP cells in medium) was shown. B) LNCaP cells were treated with 5nM 
R1881 and 10µg/ml cycloheximide (c) in phenol red-free RPMI for 8 and 24 hours. 
STAT3 expression was determined by Western blot and β-actin was shown for loading 
control. C) LNCaP cells were serum deprived and pre-treated with 5nM R1881 in phenol 
red-free RPMI in the presence or absence of 10µM flutamide for 24 hours followed by 
incubation with 5nM R1881 and 25µM LY294002 for 1 hour. STAT3 and Bcl-xL 
expression was determined by Western blot and β-actin was shown for loading control. 
D) LNCaP cells were serum deprived and pre-treated with 5nM R1881 in phenol red-free 
RPMI for 24 hours followed by incubation with 5nM R1881 and 25µM LY294002 for 
1.5 hour. Nucleus isolation was done as described in Materials and Methods and Western 
blot was performed to detect STAT3 expression in both nucleus (N) and cytosolic (C) 
fractions. PARP was detected to show as a marker for nucleus fraction. All results shown 
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Figure 15. STAT3 is involved in androgen-mediated PI3-K independent survival. 
LNCaP cells were transfected with 50nM control (co si) or STAT3 (STAT3 si) siRNA. 
48 hours post-transfection, the cells were serum deprived or pre-treated with 5nM R1881 
in phenol red-free RPMI for 24 hours followed by incubation with 25µM LY294002 
(LY) and 5nM R1881 for 9 and 24 hours. A) Efficiency of STAT3 repression was 
determined by Western blot and shown as a representative blot out of six independent 
experiments. Cells death was measured by B) caspase 3 activity and C) subG1 population 
determination by PI staining. (D and E) Results shown in (B) and (C) respectively were 
calculated as percentage of decrease in LY-induced cell death in androgen-treated cells 
over control cells and shown as mean ± S.E. from three independent experiments done in 
duplicates. * p<0.05 and ** p<0.01 
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3.1.6   Role of AR and STAT3 in mitochondria 
 Recently it has been found that STAT3, besides its translocation to the nucleus 
upon activation by phosphorylation, could also localize to the mitochondria (Lufei et al, 
2003). Next we wanted to find out if STAT3 in LNCaP cells could also translocate to the 
mitochondria upon androgen treatment and if AR, another nuclear receptor, could also 
translocate to the mitochondria. Surprisingly, R1881 induced an increase in both AR and 
STAT3 in the mitochondria after 1.5 hours of treatment and this could not be inhibited by 
blocking of PI3-K activity by LY294002 (Figure 16A). The increase in STAT3 in the 
mitochondria could be due to the increase in STAT3 expression when cells were exposed 
to R1881. Co-immunoprecipitation was then performed to determine if the co-
localization of AR and STAT3 could be due to their interaction. AR did not co-
immunoprecipitate with STAT3, indicating that it was likely that STAT3 did not interact 
with AR (Figure 16B). Thus the localization of AR and STAT3 at the mitochondria upon 
R1881 treatment could probably be a distinct event and not due to their interaction. 
However, the role of STAT3 and AR at the mitochondria in the presence of androgen was 
unclear. Their mitochondria localization upon androgen and LY294002 treatment could 
probably suggest that both AR and STAT3 might be involved in the survival at the 



































Figure 16. Androgen receptor and STAT3 translocates to the mitochondria upon 
androgen treatment but AR did not interact with STAT3. A) LNCaP cells were 
serum deprived and pre-treated with 5nM R1881 in phenol red-free RPMI for 24 hours 
before being incubated with 5nM R1881 and 25µM LY294002 (LY) for 1.5 hour. 
Mitochondria were isolated and Western blot was carried out to determine AR and 
STAT3 expression in mitochondria (m) and cytosolic (c) fractions. VDAC and Cu/Zn 
SOD were shown as loading control for mitochondria and cytosolic fraction respectively. 
B) LNCaP cells were treated as in (A) and total cell lysates were collected for 
immunoprecipitation with anti-STAT3 antibody. Western blot was performed to 
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3.1.7   EGFR was not involved in androgen-mediated survival 
 
In addition to Bcl-xL, androgen treatement induced another survival protein 
EGFR which has been shown to be involved in prostate cancer survival.  EGFR has been 
shown to interact with androgen receptor and promote metastasis of prostate tumour 
(Bonaccorsi et al, 2003). In addition, one report suggested that EGFR could be involved 
in androgen-induced protection from apoptotic effects of LY294002 (Torring et al, 
2003). The next step to understand androgen-mediated survival is to verify if EGFR plays 
any role in PI3-K independent survival enabled by androgen.  
First androgen was observed to increase EGFR expression in LNCaP cells and 
this was not affected by LY294002 treatment for up to 6 hours (Figure 17A). However 
we could not detect significant increase in phosphorylated EGFR unlike reported by 
Torring et al. EGFR was not significantly increased by serum and its expression only 
slightly increased when treated with serum for 6 hours. This could mean that EGFR was 
unlikely to be involved in the survival mediated by serum. No EGFR was detected for 
cells treated with EGF although high level of phosphorylated EGFR was detected. This 
was probably due to strong activation of EGFR by EGF leading to the down regulation of 
EGFR by internalization and subsequent degradation (Sorkin, 2001).  
Androgen, in addition to up-regulating EGFR, down-regulates ErbB2 which is 
another member of the ErbB receptor family. Both phosphorylated and total level of 
ErbB2 were observed to be repressed in the presence of R1881 (Figure 17A). This 
observation was interesting as it was similar to the effect of androgen on the alteration of 
the ratio of anti-apoptotic Bcl2 family proteins whereby androgen up-regulates Bcl-xL 
and down-regulates Bcl2. We found that this high EGFR to ErbB2 ratio was a phenotype 
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of androgen-independent prostate cancer models PC3 and DU145 (Figure 17B) which 
was similar to the high Bcl-xL to Bcl2 ratio observed earlier in Figure 10.  
 EGFR activation has been reported to lead to the activation of STAT3 and one 
study showed a strong correlation between EGFR expression and nuclear STAT3 in 
breast cancer cells (Berclaz et al, 2001). Since we found that STAT3 played an important 
role in androgen-mediated survival in LNCaP in Figure 15, next we tested if the 
expression of EGFR influenced the STAT3 level or vice versa. No observable difference 
in EGFR expression was detected in LNCaP cells transfected with STAT3 siRNA and 
similarly no difference in STAT3 expression was seen in cells transfected with EGFR 
siRNA compared to cells transfected with control siRNA (Figure 18). Thus it is likely 
that R1881 mediated the increase of EGFR and STAT3 expression through independent 
signaling mechanisms.   
Earlier we have presented findings suggesting that Bcl-xL was essential in 
androgen mediated PI3-K survival. Interestingly, we observed that EGFR expression was 
repressed when Bcl-xL was silenced by siRNA transfection (Figure 19A), suggesting that 
EGFR could probably be a downstream effect of androgen-induced increase in Bcl-xL 
expression. To our knowledge, EGFR expression has yet to be shown to be regulated by 
Bcl-xL. Since the expression of EGFR appearred to be affected by androgen and Bcl-xL, 
the next question was whether EGFR could participate in androgen mediated survival. 
 EGFR activity was inhibited by a specific EGFR inhibitor AG1478 and Bcl-xL 
expression was determined by Western blot. It was observed that inhibiting EGFR 
activity did not affect Bcl-xL expression and androgen could still increase Bcl-xL 
expression in the presence of AG1478 for 8 hours (Figure 19C). Thus androgen increased 
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Bcl-xL expression without involving EGFR activity. This was not due an inefficient 
inhibition of EGFR by AG1478 since the concentration used effectively blocked ERK 
phosphorylation by EGF (Figure 19B). 
 The repression of EGFR by siRNA transfection in LNCaP did not affect androgen 
inhibition of cell death as reflected by the caspase 3 activity (Figure 20A and C) and 
subG1 population (Figure 20B and D) determined when LNCaP cell were treated with 
LY294002 and androgen. In summary, although androgen did induce EGFR expression, 








































































Figure 17. Andrgogen induced the up-regulation of EGFR and down-regulation of 
ErbB2 receptors. A) LNCaP cells were serum deprived and pre-treated with 5nM R1881 
for 24 hours in phenol red-free RPMI before being incubated with 10% charcoal-stripped 
serum (cs), 100ng/ml EGF and 5nM R1881 with or without 25µM LY294002 (LY) for 1 
and 6 hours. B) LNCaP, PC3 and DU145 cells were serum deprived or pre-treated with 
5nM of R1881 in phenol red-free RPMI for 24 hours before being incubated with 5nM 
R1881 and 25µM LY294002 for 1 and 8 hours. EGFR and ErbB2 expression were 
detected by Western blot. Densitometry analysis was carried out and relative intensity of 
bands were normalized to β-actin and expressed as percentage of control (LNCaP cells in 

























































































































































































































































Figure 18. Effect of EGFR and STAT3 repression on STAT3 and EGFR expression. 
LNCaP cells were transfected with mock, 50nM control (Co si), EGFR (EGFR si) or 
STAT3 (STAT3 si) siRNA and cell lysates were collected 48 hours post-transfection for 
Western blot to determine EGFR and STAT3 protein expression. Results shown were 
representative blots from two independent experiments.  
 




















Figure 19. EGFR activity is not required for androgen-induced Bcl-xL expression 
but EGFR expression is affected by Bcl-xL expression. A) LNCaP cells were 
transfected with mock, control (Co si) and Bcl-xL siRNA (Bcl-xL si). Cell lysates were 
collected 48 hours post-transfection for Western blot to determine EGFR expression. B) 
LNCaP cells were serum deprived for 24 hours and pre-treated with 10µM AG1478 for 1 
hour before incubated with 100ng/ml EGF for another hour. Phosphoylated ERK was 
determined by Western blot to show efficiency of EGFR inhibition by AG1478. C) 
LNCaP cells were serum deprived and pre-treated with 5nM R1881 for 24 hours in 
phenol red-free RPMI. The cells were then pre-treated with 10µM AG1478 for 1 hour 
before being incubated with 5nM R1881 and 25µM LY294002 (LY) for another 1 and 8 
hours. Western blot was carried out to detect Bcl-xL expression. β-actin was detected for 
loading control and all results shown were representative blots from two independent 
experiments. 
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Figure 20. EGFR is not involved in androgen-mediated PI3-K independent survival.  
LNCaP cells were transfected with control (Co si) or EGFR siRNA (EGFR si) and 48 
hours post-transfection the cells were serum deprived and pre-treated with 5nM R1881 in 
phenol red-free RPMI for 24 hours before incubated with 5nM R1881 and 25µM 
LY294002 (LY) for 9 and 24 hours. Cell death was assessed by A) caspase 3 activtiy and 
B) subG1 population determination by propidium iodide staining as described in 
Materials and Methods. (C and D) Results shown in (A) and (B) respectively were 
calculated as percentage of decrease in LY-induced cell death in androgen-treated cells 
over control cells and shown as mean ± S.E. from three independent experiments done in 
duplicates. Inset showed the efficiency of EGFR repression.  
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3.1.8   Role of Bcl2 family proteins during inhibition of cell death by androgen 
 To follow-up on the results suggesting that Bcl-xL might play an essential role in 
mediating androgen rescue of apoptosis caused by inhibition of PI3-K, it would be 
interesting to understand how Bcl-xL blocked cell death in LNCaP.  
 
3.1.8.1   Bad 
 The expression of Bcl2 family members in the mitochondrial and cytosolic 
fractions of LNCaP cells following treatment with LY294002 and R1881 were assessed. 
In accordance with results shown in Figure 6, treatment with LY294002 led to the 
dephosphorylation of Bad even in the presence of R1881 (Figure 21A). 
Dephosphorylation of Bad caused by LY294002 alone led to an increase in Bad 
mitochondrial translocation. Interestingly, in the presence of LY294002, R1881 inhibited 
the mitochondrial translocation of Bad even though Bad was dephosphorylated (Figure 
21A and B). Hence, one possible mechanism by which R1881 prevented LY294002-
induced cell death in LNCaP cells could be by inhibiting Bad from translocating to the 
mitochondria to mediate its pro-apoptotic functions.  
 
3.1.8.2   Bax 
 In addition to an increase in Bad translocation to the mitochondria, LY294002 
also led to an increase in mitochondrial translocation of Bax (Figure 21A and C). It was 
observed that there was also an increase in Bax translocation to the mitochondria in cells 
treated with R1881 alone and a similar level of Bax translocation was found in cells 
treated with R1881 and LY294002. R1881 was found to induce Bax activation as an 
 Results 68
increase in Bax conformational change to expose its N-terminal was detected at both 9 
and 24 hours (Figure 22). However, combined treatment with R1881 and LY294002 
induced less Bax activation in LNCaP cells than treatment with LY294002. Charcoal-
stripped serum (cs) was shown as a control treatment which did not induced any Bax 
activation. Although androgen itself induced some level of Bax activation, it did not 
affect androgen to mediate PI3-K independent survival, indicating that the level of 
androgen-induced Bax activation was probably not sufficient to compromise cell 
survival. Therefore, the inhibition of Bad translocation rather than Bax translocation to 
the mitochondria seemed to be more important in androgen-mediated survival.   
 
3.1.8.3   Bcl-xL and Bcl2 
As for the anti-apoptotic members of the Bcl2 family of proteins, R1881 
repressed the expression of Bcl2 in the mitochondria (Figure 21A) which reiterated our 
previous data shown in Figure 8A. R1881 induced Bcl-xL expression which was 
observed in both the mitochondrial and cytosolic fractions (Figure 21A and D). With 
the repression of Bcl2, a major anti-apoptotic Bcl2 family member, Bcl-xL would 
probably play an even essential role in counteracting the effect of pro-apoptotic members 
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Figure 21. Effect of androgen on mitochondria translocation of Bcl2 family proteins.  
LNCaP cells were serum deprived and pre-treated with 5nM R1881 in phenol red-free 
RPMI for 24 hours before being incubated with 5nM R1881 and 25µM LY294002 (LY) 
for 1.5 hour. Mitochondria were isolated as described in Materials and Methods. A) 
Western blot was carried out to determine various Bcl2 family proteins in both 
mitochondria (m) and cytosolic (c) fractions. VDAC and Cu/Zn SOD were shown as 
loading control for mitochondria and cytosolic fraction respectively. Densitometry 
analysis of B) mitochondrial Bad, C) mitochondrial Bax, D) mitochondrial and cytosolic 
Bcl-xL were calculated as % of control (cells in medium) and normalized to VDAC or 
Cu/Zn SOD. Results shown were representative from three independent experiments. 
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Figure 22. Androgen induced Bax activation but blocked LY294002-induced Bax 
activation. LNCaP cells were serum deprived and pre-treated with 5nM R1881 in phenol 
red-free RPMI for 24 hours before being incubated with phenol red-free serum-free 
medium (ns), 10% charcoal-stripped serum (cs) and 5nM R1881 in the presence or 
absence of 25µM LY294002 (LY) for 9 and 24 hours. Amount of activated Bax was 
determined by flow cytometry as described in Materials and Methods. Result was shown 
as mean ± S.E of three independent experiments done in duplicates. * p < 0.01 
 
 
3.1.8.4   Bcl-xL and Bad 
Since we showed in Figure 21 that androgen could inhibit mitochondrial 
translocation of Bad and androgen-induced Bcl-xL expression was found in both 
cytosolic and mitochondrial fractions, next we wanted to find out if an increase in Bcl-xL 
could prevent Bad from translocating to the mitochondria. The interaction of Bad and 
Bcl-xL in both the cytosolic and mitochondrial fractions of R1881-treated LNCaP cells 
was determined by co-immunoprecipitation with anti-Bcl-xL antibody. Bad and Bcl-xL 
interaction was only found in the mitochondria fraction but no detectable Bad-Bcl-xL 
interaction was found in the cytosolic fractions of LNCaP cells treated with R1881 or 
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LY294002 (Figure 23). Thus it was unlikely that androgen-induced cytosolic Bcl-xL 
could inhibit Bad mitochondrial translocation by interaction in the presence of 
LY294002. Therefore, there could be other mechanism through which androgen inhibited 












Figure 23. Bad and Bcl-xL interaction is found only in the mitochondria. LNCaP 
cells were serum deprived and pre-treated with 5nM R1881 in phenol red-free RPMI for 
24 hours before being incubated with 25µM LY294002 (LY) and 5nM R1881 for 1.5 
hours. Sub-cellular fractionation was performed to collect the mitochondrial and 
cytosolic fractions for immunoprecipitation with anti-Bcl-xL antibody. Co-
immunoprecipitation of Bad was determined by Western blot as descrbed in Materials 
and Methods. A representative blot out of two independent experiments was shown. 
 
 
3.1.8.5   Bak  
 Previously it has been shown that the repression of Bax by siRNA transfection 
prevented LY294002-induced apoptosis whereas the repression of Bad produced similar 
results but to a lesser extent,  supporting the role of Bad as a facilitator and Bax as an 
executor of apoptosis induced by inhibition of PI3-K (Chao and Clement, 2006). We 
showed in Figure 21 and 22 that R1881 could prevent LY294002-induced apoptosis via 
inhibition of Bad and Bax activation. Next we tested if Bak, another pro-apoptotic 
member of the Bcl2 family, participated in apoptosis induced by inhibition of PI3-K.  
IP: Bcl-xL





To assess if Bak is involved in androgen-mediated inhibition of LY294002-
induced apoptosis, cell death in the absence of Bak expression was measured. LY294002-
treated LNCaP cells transfected with Bak siRNA showed a decrease in caspase 3 activity 
and subG1 population (Figure 24A and B respectively) compared to that of cells 
transfected with control siRNA, indicating that apoptosis caused by the inhibition of PI3-
K required Bak expression. Moreover, androgen reduced caspase 3 activity in 
LY294002-treated cells to a level almost close to that of Bak-repressed cells.  
Furthermore, incubation of LNCaP cells with LY294002 in serum-free medium 
induced an increase in the activation of Bak as detected by the amount of Bak with its N-
terminal being exposed. Addition of R1881 to LY294002-treated cells reduced the 
activation of Bak, implicating that androgen could probably inhibit cell death by blocking 
the activation of Bak (Figure 24C). Treatment with staurosporine (STS) served as a 











































































Figure 24. Bak is involved in cell death induced by inhibition of PI3-K. A) LNCaP 
cells were transfected with control (Co si), Bak (Bak si) or Bax (Bax si) siRNA and 48 
hours post-transfection the cells were serum deprived and pre-treated with 5nM R1881 in 
phenol red-free RPMI for 24 hours before being incubated with 5nM R1881 and 25µM 
LY294002 (LY). Cell death was assessed by caspase 3 activity after 3 and 6 hours and B) 
sub G1 population determination by propidium iodide staining after 24 hours. Inset 
shows the efficiency of Bak and Bax repression determined by Western blot. C) LNCaP 
cells were serum deprived and pre-treated with 5nM R1881 in phenol red-free RPMI for 
24 hours before incubated with 5nM R1881, 25µM LY294002 (LY) and 2µM 
staurosporine (STS) for 9 and 24 hours. Amount of activated Bak was determined by 
flow cytometry as described in Materials and Methods. Results were shown as mean ± 
S.E of three independent experiments done in duplicates. * p < 0.01 





3.1.8.6   Bcl-xL and Bak  
 LY294002 induced apoptosis in LNCaP cells by inducing the activation of Bak 
and androgen inhibited LY294002-induced apoptosis by increasing Bcl-xL expression. 
Thus, the next question was to find out whether androgen-induced Bcl-xL expression 
rescued cell death, caused by the inhibition of PI3-K, through blocking the action of Bak. 
Anti-apoptotic Bcl2 family proteins bind to pro-apoptotic Bcl2 proteins to inhibit its 
death-inducing action. The pull-down of Bcl-xL from immunoprecipitated Bak samples 
was assessed for Bcl-xL and Bak interaction, which was further confirmed by reciprocal 
pull-down of Bak from Bcl-xL-immunoprecipitated samples.  
LY294002 caused the reduction in Bcl-xL and Bak interaction which 
corroborated with the results showing that LY294002-induced Bak activation. Activated 
Bak was likely to be unbound from Bcl-xL and oligomerized to induce cell death. 
LY294002 also induced an increase in Bad and Bcl-xL interaction which could also 
probably free Bak from being bound to Bcl-xL. Addition of R1881 to LNCaP cells 
increased Bcl-xL and Bak interaction, but not Bcl-xL and Bad interaction, as compared to 
cells in medium and this was probably due to the increase in Bcl-xL expression caused by 
R1881. Interestingly, combined treatment (LY294002 and R1881) of LNCaP cells 
resulted in higher interaction of Bcl-xL and Bak than that in LY294002-treated cells 
(Figure 25A). The increase in Bad and Bcl-xL association was still observed when cells 
were treated simultaneously with androgen and LY294002, which could not inhibit Bak 
and Bcl-xL interactions. This could probably explain how androgen inhibited LY294002-
induced cell death as the increase in interaction of Bcl-xL and Bak was likely to inhibit 
pro-apoptotic action of Bak.  
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 To further prove that androgen inhibition of LY294002-induced cell death 
correlates with the level of Bak and Bcl-xL interaction and since Bak is mainly localized 
to the outer mitochondria membrane (Input lane in Figure 25B; Griffiths et al, 1999), the 
interaction of Bak to Bcl-xL was assessed in the mitochondrial fractions of treated cells. 
Incubation with LY294002 caused a decrease in Bak and Bcl-xL interaction but an 
increase in Bad and Bcl-xL interaction in the mitochondria, compared to cells grown in 
feeding medium. R1881 led to an increase in the interaction of Bak and Bcl-xL at the 
mitochondria and this was also maintained in the presence of LY294002 even though 
Bad and Bcl-xL interaction remained higher than that of untreated cells (Figure 25B). 
However, no interaction of Bcl-xL with Bak or Bad was observed in the cytosol. Bcl2 
and Bax were observed to interact with neither Bcl-xL nor Bak. The lack of Bax and Bad 
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Figure 25. Androgen induced an increase in interaction of Bcl-xL with Bak. LNCaP 
cells were serum deprived and pre-treated with 5nM R1881 in phenol red-free RPMI for 
24 hours before being incubated with 5nM R1881 and 25µM LY294002 (LY) for 1.5 
hour.  Immunoprecipitation with anti-Bak and anti-Bcl-xL antibodies was carried out on 
A) total cell lysates or B) mitochondria and cytosolic fractions. Western blot was 
performed to detect for the pull-down of Bcl-xL, Bak and Bad proteins. Results shown 
were representative blots from two independent experiments. Densitometry analysis of 
relative intensity of the bands was calculated as percentage of control (cells in medium) 






















































































































































































3.2   Survival pathway in androgen-insensitive LNCaP  
3.2.1   MAPK pathway in AR-negative LNCaP 
 LNCaP is the most commonly used androgen-sensitive prostate cancer model. 
Due to prolonged passages, we have derived a sub-line of LNCaP which has lost the 
expression of androgen receptor and does not respond to androgen (AR-negative 
LNCaP). By comparing AR-negative LNCaP and LNCaP, we observed that there was 
lower level of basal phosphorylated AKT in AR-negative LNCaP than wild-type LNCaP 
(Figure 26A). The expression of AR was shown to confirm the loss of AR in AR-
negative LNCaP. This indicated that the activity of the AKT pathway could be lower in 
AR-negative LNCaP and other signaling pathways could probably play a role in cell 
survival in AR-negative LNCaP cells. This is plausible since we have also shown (Figure 
3) that PI3-K independent survival pathways also existed in AR-negative LNCaP. 
 Indeed there was higher level of phosphorylated ERK and its downstream target 
p90rsk in AR-negative LNCaP cells than that in LNCaP cells, indicating higher activity 
of the MAPK pathway in AR-negative LNCaP cells (Figure 26B). There was also a 
higher level of phosphorylated Bad in AR-negative LNCaP cells than that in LNCaP cells 
which could possibly imply better survival in AR-negative LNCaP than LNCaP, a 
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Figure 26. Androgen receptor-negative LNCaP cells have higher activation of the 
MAPK pathway than wild type LNCaP cells. LNCaP and AR-negative LNCaP cells 
were serum deprived and pre-treated with 5nM R1881 in phenol red-free RPMI medium 
for 24 hours before being incubated with 25µM LY294002 (LY) and 5nM R1881 for A) 
1 and 8 hours and B) 1 hour. Western blot was performed to detect the expression of 
respective proteins. β-actin was shown for loading control and all results were shown as a 
































































































































































3.2.2   Cross talk between AKT and MAPK signaling pathway in AR-negative 
LNCaP 
 Inhibition of PI3-K by LY294002 led to the dephosphorylation of ERK and 
p90rsk in AR-negative LNCaP cells. This effect probably in turn led to the observation of 
a slight dephosphorylation of Bad at S75 in the presence of LY294002 (Figure 26B). 
Here we showed that the inhibition of PI3-K by LY294002 not only blocked AKT 
downstream signaling pathway but it also led to the deactivation of the MAPK pathway 
in AR-negative LNCaP cells. This implied that there could be a possible cross-talk 
between the PI3-K/AKT and MAPK signaling pathways at least in AR-negative LNCaP 
cells. 
 To confirm that the effect of LY294002 on the phosphorylation of the 
ERK/p90rsk/Bad module was due to inhibition of PI3-K, another PI3-K inhibitor 
wortmannin, which is a cell-permeable fungal metabolite, was used. Similar to 
LY294002, wortmannin also caused the dephosphorlation of AKT as well as MEK and 
ERK in AR-negative LNCaP cells (Figure 27). Therefore, these data demonstrated that 
the inhibition of ERK phosphorylation was a downstream effect of inhibition of PI3-K.  
 Next we were interested to understand how the inhibition of PI3-K could lead to 
the inhibition of MAPK signaling. Activation of PI3-K led to an increase in the PIP3 
levels, which could recruit AKT to the membrane, which in turn could result in 
phosphorylation and activation of AKT. To determine if the inhibition of ERK 
phosphorylation in AR-negative LNCaP cells was due to the inhibition of PI3-K or its 
downstream signaling molecules, we tested if the expression of PDK1 or AKT could 
affect ERK phosphorylation in AR-negative LNCaP cells. The repression of PDK1 by 
 Results 80
siRNA transfection prevented the phosphorylation of ERK whereas, in contrast, the 
repression of AKT did not dephosphorylate ERK (Figure 28). Hence, the 
dephosphorylation of ERK in AR-negative LNCaP cells treated with LY294002 could 
likely happen upstream of AKT and involve PDK1 as repression of AKT was insufficient 
to induce ERK dephosphorylation. 
 PDK1 is the kinase responsible for the phosphorylation of AKT at T308. The 
repression of PDK1 in LNCaP cells inhibited the phoshorylation of AKT at S473 as well. 
Thus this could indicate that blocking the phosphorylation of AKT at T308 by PDK1 
would prevent its phosphorylation at S473. However, the effect of PDK1 repression on 
phosphorylation of AKT at T308 was not shown because its level in LNCaP was too low 
to be detected by Western blot.  
 Inhibition of PI3-K/AKT pathway by LY294002 in the absence of growth factors 
led to cell death in AR-negative LNCaP cells as shown previously in Figures 3B and C. 
Our results have shown that LY294002 could block both the PI3-K/AKT and ERK 
signaling pathway in AR-negative LNCaP and the repression of PDK1 could produce a 
similar effect. Thus we were interested to find out if the repression of PDK1 in AR-
negative LNCaP cells could also lead to cell death. Neither the repression of PDK1 nor 
AKT expression by siRNA transfection induced significant cell death in AR-negative 
LNCaP cells as assessed by caspase 9 activtiy, caspase 3 activity and subG1 population  
(Figure 29A , B and C respectively). In contrast, treatment with LY294002 led to 
significant apoptosis in AR-negative LNCaP cells. Moreover, neither PDK1 nor AKT 
repression could significantly dephosphorylate Bad at S75 (Figure 28). Hence the 
repression of PDK1 was insufficient to induce apoptosis in AR-negative LNCaP cells. 
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Apoptosis induced by treatment of AR-negative LNCaP cells with LY294002 required 
more than the inhibition of PI3-K/AKT and ERK signaling pathway and LY294002 could 



























Figure 27. PI3-K inhibitors blocked MAPK activity in AR-negative LNCaP cells. 
AR-negative LNCaP cells were serum deprived for 24 hours and incubated with 25µM 
LY294002 (LY) or 50-200nM of wortmannin (W) in the absence (ns) or presence of 10% 
serum (s) for 1 hour. Western blot was performed to detect for expression of various 
proteins. β-actin was detected for loading control and results were shown as a 
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Figure 28. Repression of PDK1 but not AKT led to the dephosphorylation of ERK 
in AR-negative LNCaP. AR-negative LNCaP cells were transfected with 20-100nM 
siRNA specific for AKT (AKT si), PDK1 (PDK1 si) or control (Co si) siRNA. 48 hours 
post-transfection, Western blot was performed to detect for expression of various proteins 
and β-actin was detected for loading control Results were shown as a representative blot 
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Figure 29. Repression of PDK1 or AKT under serum-free condition did not induce 
apoptosis in AR-negative LNCaP cells. AR-negative LNCaP cells were transfected 
with control (Co si), AKT (AKT si) or PDK1 (PDK1 si) siRNA and 48 hours post-
transfection, the cells were serum deprived for 24 hours and incubated with serum-free 
RPMI or 25µM LY294002 (LY). A) Caspase 9 activity and B) caspase 3 activity was 
detected after 6, 12 and 24 hours. C) SubG1 population was determined by propidium 
iodide staining after 24 hours. Inset shows the representative Western blot determining 
the silencing efficiency of AKT and PDK1 siRNA transfection. Results (B and C) were 
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3.2.3   Computational modeling of signaling pathways 
Our results demonstrated that the blockage of PI3-K activity by PI3-K inhibitor 
not only affected the AKT pathway but also the ERK pathway. To better understand the 
cross-talk between the two major signaling pathways in AR-negative LNCaP cell line, a 
computational modeling of the system was used.  
The advantage of computational models is the ability to identify cellular 
components and the interactions between these components, enabling the study of 
relationship between several signaling pathways. In addition, using a computational 
model also allows for simulations so that we could have preliminary (though not 
validated) results on the effect of changes to the variables in the signaling model. Such 
simulation data can aid in and refine our hypothesis although such data still needs to be 
verified experimentally. The Hybrid Functional Petri Net (HFPN) (Matsuno et al., 2003) 
was used as the modeling framework. A decompositional approach, which exploited the 
structure of a large pathway model to break it into smaller components, was adopted to 
answer the parameter estimation problem in signaling pathway modeling. Details on the 
method of generating the computational model (Figure 30) and data used for parameter 
estimation could be found in the publication by Koh et al, 2006.  
Earlier our data showed that the silencing of PDK1 expression by siRNA 
transfection caused the dephosphorylation of ERK. We hypothesized that PDK1 could 
affect ERK activation in AR-negative LNCaP through MEK (shown in bold test arcs in 
Figure 30). Sato et al (2004) has found that PDK1 could phosphorylate MEK and thus 
activate it. Simulation on the model by reducing the level of PDK1 to mimic the 
repression by siRNA transfection produced similar result to those shown in Figure 28. 
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The level of MEK and ERK phosphorylation decreased with decreasing amount of 
simulated PDK1 (Figure 31). Thus the model supported the hypothesis that PDK1 could 
activate ERK through MEK. However, additional experiments to test the phosphorylation 
of MEK, when PDK1 expression is repressed, are required to validate the hypothesis. 
With more experiments to validate and refine the model, more simulations can be 
performed to aid in better understanding the interactions of multiple signaling pathways 
in AR-negative LNCaP cell line.  
 
 
Figure 30. HFPN model of the AKT and MAPK signaling pathways in AR-negative 
LNCaP cell line. The computational model is decomposed into 6 components: (a) PI3-
K/AKT signaling pathway, (b-e) Raf/MEK/MAPK signaling pathway and (f) Bcl2 family 
proteins. The hypothesized link between the two pathways is shown by bold test arcs. 
(from Koh et al, 2006) 
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Figure 31. Simulation results of MEK and ERK phosphorylation status during 
PDK1 repression. The model was simulated with decreasing amount of PDK1 (arbitrary 











4.   DISCUSSION 
4.1   Survival pathway induced by PI3-K/AKT signaling in LNCaP 
 Dysfunctional regulation of apoptosis can manifest as a variety of disease state 
such as tumourigenesis or autoimmune disorders. Defective apoptosis is a common 
feature of various cancers and an underlying cause of drug resistance. Thus it is crucial to 
understand how cancer cells by-pass the apoptotic signal and survive in the absence of 
growth factors in order to aid in developing better therapeutic agents to eliminate 
tumours.  
Constitutive activation of PI3-K due to a defective PTEN in LNCaP cells leads to 
a strong survival signal induced by the AKT signaling pathway. Thus the PI3-K/AKT 
signaling has been reported to be the dominant growth factor-activated survival pathway 
in LNCaP since inhibition of PI3-K by various specific inhibitors such as LY294002 and 
wortmannin induced cell death in LNCaP cells whereas in contrast inhibitors of other 
signaling pathways such as rapamycin (ribosomal S6 kinase pp70S6K inhibitor), PD98059 
(inhibitor of MEK) and casodex (anti-androgen) did not significantly induce cell death 
(Lin et al, 1999). The inhibition of PI3-K activity in LNCaP cells has been shown to lead 
to apoptosis which could be reversed by various growth factors such as serum, EGF and 
androgen, supporting the presence of a PI3-K independent survival pathway (Carson et 
al, 1999; Lin et al, 1999). Recent work by Chao and Clement (2006) has reported on the 
signaling induced by serum and EGF that blocked apoptosis triggered by inhibition of 
PI3-K in LNCaP cells and showed that Bad played a critical role in determining cell fate 
in this system. However, the mechanism of androgen-mediated inhibition of cell death 
has yet to be clearly elucidated.  
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4.2   Activation of AR by androgen could rescue LNCaP cells from cell death 
induced by inhibition of PI3-K 
 Here we investigated the signaling mechanism behind androgen-induced survival 
pathway in the prostate cancer model, LNCaP. In contrast to serum and EGF, the 
synthetic androgen R1881 could block cell death induced by inhibition of PI3-K in 
LNCaP cells only after 24 hours of pre-treatment. This implied that androgen could 
induce a genomic effect and probably require gene transcription and protein synthesis to 
participate in the inhibition of cell death. Thus the inhibition of cell death by androgen 
could be attributed to the effect of the AR as a ligand-induced transcription factor and 
unlikely to be due to the rapid non-genotrophic signaling of AR that activated signaling 
pathways such as the MEK/ERK pathway (Peterziel et al, 1999). 
 Indeed, we showed that androgen-induced cell survival was mediated by AR since 
androgen could not rescue cells from apoptosis triggered by inhibition of PI3-K in 
LNCaP cells lacking AR expression. Moreover the role of AR as a transcription factor 
was essential in promoting cell survival as the presence of the anti-androgen flutamide, 
which blocks AR activity as a transcription factor, prevented androgen from rescuing 
cells from LY294002-induced apoptosis. 
 
4.3   Androgen and EGF induced PI3-K independent cell survival in LNCaP cells 
through distinct pathways  
 Previously, our laboratory has reported on the mechanism whereby EGF could 
mediate PI3-K independent cell survival in LNCaP cells (Chao and Clement, 2006). EGF 
treatment maintained the phosphorylation of Bad at S75 in the presence of LY294002 by 
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activation of the MEK/ERK/RSK1 module. The phosphorylation of Bad in turn led to 
reduced translocation of Bad to the mitochondria, thus preventing its pro-apoptotic 
function. However, treatment with androgen did not induce the phosphorylation of MEK, 
ERK and RSK1. Androgen treatment could not maintain the phosphorylation of Bad at 
S75 in LNCaP cells when triggered with LY294002. Pre-treatment of LNCaP cells with 
the MEK inhibitor U0126 also did not prevent androgen to inhibit cell death triggered by 
inhibition of PI3-K. Thus androgen mediated a PI3-K independent cell survival through 
mechanism distinct from EGF.  
 
4.4   Androgen induced expression of the anti-apoptotic Bcl-xL to protect LNCaP 
cells from apoptosis induced by inhibition of PI3-K 
 Bcl-xL, an important anti-apoptotic protein of the Bcl2 family, has been 
implicated in survival pathways in prostate cancer cell lines (Lebedeva et al, 2000; Yang 
et al, 2003). In this study we reported that androgen could induce the expression of Bcl-
xL and this increase in Bcl-xL expression was critical in mediating PI-3K independent 
cell survival in LNCaP cells. We showed that androgen-induced Bcl-xL expression 
required the expression of AR and its activity as a transcription factor. An interesting 
observation was the corresponding decrease in the expression of Bcl2, another anti-
apoptotic protein, in the presence of androgen. This androgen-induced high Bcl-xL to 
Bcl2 ratio in LNCaP was also found in the more advanced stage of prostate cancer 
models such as the PC3 and DU145 cell lines. There have been reports showing that 
androgen could repress Bcl2 expression (Bruckheimer et al, 2003; Huang et al, 2004) but 
the rationale for the up-regulation of Bcl-xL and down-regulation of Bcl2 by androgen 
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remained obscure. These suggested that Bcl-xL rather than Bcl2 could play a more 
important role in regulation of apoptosis in prostate cancer models. Indeed Bcl-xL is 
critical in mediating PI3-K independent cell survival in LNCaP cells as the repression of 
Bcl-xL abolished the ability of androgen to protect LNCaP cells from apoptosis induced 
by the inhibition of PI3-K. 
 
4.5   Role of STAT3 in androgen-mediated PI3-K independent cell survival 
 Links between STAT3 and AR signaling has been revealed recently and it has 
been shown that STAT3 could participate in cell protection from apoptosis in prostate 
cancers (Barton et al, 2004). In agreement with these reports, we provided evidence that 
STAT3 could be involved in PI3-K independent cell survival induced by androgen in 
LNCaP cells.  
 As discussed earlier, Bcl-xL plays an important role in protecting LNCaPs from 
apoptosis. Our results showed that androgen-induced Bcl-xL expression was unlikely to 
be due to activation of NFκB, a transcription factor for regulating Bcl-xL expression. 
STAT3 has been known to be one of the transcription factors besides NFκB for the 
regulation of Bcl-xL expression. Our data supported that androgen could induce the 
expression of Bcl-xL through STAT3 since the repression of STAT3 by siRNA gene 
silencing prevented androgen-induced Bcl-xL expression but it did not affect its basal 
expression.  
Next we also showed that androgen induced the phosphorylation and expression 
of STAT3 and this could be blocked by addition of the protein synthesis inhibitor 
cycloheximide or the anti-androgen flutamide. These indicated that androgen induction of 
 Discussion 91
STAT3 phosphorylation and expression was unlikely to be due to a direct effect but could 
be due to the transcriptional activity of AR. We proposed that the activated AR induced 
by androgen treatment could probably lead to the increase in STAT3 expression which in 
turn resulted in an increase in its phosphorylation. This was unlikely to be due to AR 
acting on a STAT3 kinase to increase its phosphorylation since protein synthesis was 
required and androgen-mediated cell survival most likely involved a genomic effect. 
Moreover, we showed that activated STAT3 (phosphorylated STAT3) was already 
present in the nucleus in serum-deprived LNCaP cells and STAT3 expression was 
increased in the presence of androgen which corresponded to the increase in nuclear 
translocation of AR. Thus these results suggested that androgen could probably induce 
the expression and activation of STAT3 which in turn was responsible for the increase in 
expression of Bcl-xL thus leading to the protection from cell death.  
 However, we did not further investigate if AR could directly activate STAT3 
transcription or act through another transcription factor. Real-time polymerase chain 
reaction (PCR) could be done to determine if androgen induces an increase in STAT3 
transcription. The binding of AR to STAT3 promoter could be tested by gel-shift assay or 
chromatin immunoprecipitation (ChIP) assay to check if AR is the transcription factor 
responsible for the increase in STAT3 expression. The effect of androgen on the 
expression or activity of JAK, which is involved in STAT3 phosphorylation, could be 
tested to see if androgen acted on STAT3 expression only. 
STAT3 was further proved to be involved in androgen-mediated survival when 
the repression of STAT3 expression clearly abolished the ability of androgen to induce 
protection from cell death in LNCaP cells. A recent study revealed that the simultaneous 
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inhibition of AKT, AR and STAT3 signaling pathways by the HIV-1 protease inhibitor 
led to growth arrest and cell death in LNCaP cells, further supporting the role of STAT3 
in cell survival (Yang et al, 2005). It is therefore possible that the down-regulation of 
Bcl-xL caused by repression of STAT3 prevents androgen to rescue LNCaP cells from 
apoptosis induced by inhibition of PI3-K.  
 Surprisingly, we have found the mitochondrial localization of both AR and 
STAT3 upon androgen treatment. Both AR and STAT3 are ligand-induced transcription 
factors that translocate to the nucleus upon their activation. Recently it has been reported 
that STAT3 could localize to the mitochondria via an interaction with GRIM-19 (Lufei et 
al, 2003). The role of AR and STAT3 mitochondrial translocation was unclear and we 
could not detect the interaction of AR and STAT3 by co-immunoprecipitation. 
Immunofluorescence by confocal microscopy could be done to further determine the 
mitochondrial localization of AR and STAT3 and if both proteins could interact with 
each other.  
 
4.6   Androgen-induced EGFR expression did not participate in PI3-K independent 
cell survival 
Androgen treatment induced the expression of EGFR though we did not detect 
significant induction of EGFR phosphorylation as in the report by Torring et al (2003) 
whose work has suggested that EGFR played a role in androgen protection against cell 
death caused by LY294002. It is probable that the androgen-induced EGFR expression 
but not its activation could explain for the absence of the activation of EGFR downstream 
signaling molecules, the MEK/ERK/RSK1 module as discussed in 4.3. How androgen 
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induced EGFR expression has not been clearly understood. We provided data suggesting 
that androgen-induced EGFR expression could be downstream of Bcl-xL since the 
repression of Bcl-xL down-regulated EGFR expression. However, the effect of over-
expression of Bcl-xL on EGFR level needs to be determined to support this hypothesis.  
Although androgen mediated the increase in the EGFR expression which has been 
implicated in cell survival, we found that EGFR was unlikely to participate in the PI3-K 
independent survival pathway induced by androgen. Inhibition of EGFR did not affect 
Bcl-xL expression and moreover the silencing of EGFR expression did not affect STAT3 
expression nor prevent androgen-mediated cell survival. These suggested that EGFR 
might not be involved in androgen-mediated protection against cell death caused by 
inhibition of PI3-K.  
 
4.7   Androgen-mediated rescue of apoptosis triggered by PI3-K inhibition in 
LNCaP cells: effects on Bcl2 family proteins  
 Apoptosis is regulated by a fine balance between the pro- and anti-apoptotic 
members of the Bcl2 family of proteins. We reported that androgen induced protection 
against cell death in LNCaP cells, caused by the inhibition of PI3-K, by increasing the 
expression of anti-apoptotic Bcl-xL. However, on the other hand, androgen also repressed 
Bcl2 expression. Thus we went on to investigate how androgen could oppose the effects 





4.7.1   Bax 
 Previously our laboratory has reported that apoptosis induced by inhibition of 
PI3-K in LNCaP with LY294002 involved Bax and to a lesser extent Bad (Chao and 
Clement, 2006). Here we showed that LY294002 could induce an increase in Bax 
activation and mitochondrial translocation. Moreover, the silencing of Bax gene 
expression could significantly inhibit LY294002-induced apoptosis. Androgen alone 
could also induce some level of Bax activation and mitochondrial translocation but it was 
most likely to be insufficient to cause apoptosis in LNCaP cells. The level of Bax 
activation and mitochondrial translocation induced by combined treatment of androgen 
and LY294002 was higher than that of control cells although it was still lower than that 
induced by LY294002. Furthermore, the increase in Bcl-xL expression with androgen 
treatment was not found to interact with Bax and androgen-induced down-regulation of 
Bcl2 was unlikely to antagonize Bax pro-apoptotic activity. These data suggested that it 
was unlikely that androgen rescued LNCaP cells from apoptosis caused by LY294002 
through the inhibition of Bax activation.  
 
4.7.2   Bad 
 In the presence of survival signals, Bad is phosphorylated by several kinases and 
sequestered in the cytosol by 14-3-3 proteins. Upon its dephosphorylation, Bad 
translocates to the mitochondria to sensitize it for permeabilization and aid in the release 
of proteins such as cytochrome C (Huang and Strasser, 2000). Our data showed that 
inhibition of PI3-K by LY294002 led to dephosphorylation of the BH3-only protein Bad 
and increased its mitochondrial translocation. Treatment with androgen in the presence of 
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LY294002 did not prevent Bad dephosphorylation but reduced its mitochondrial 
translocation. It remained unclear how dephosphorylated Bad was prevented from 
translocating to the mitochondria. Recently it has been suggested that Bad could exist as 
a membrane-associated protein through its C-terminal region and shuttle between the 
mitochondria membrane and other membranes depending on its phosphorylation status. 
The authors proposed that phosphorylated Bad, which was sequestered by 14-3-3, could 
associate with cholesterol-rich membranes resulting in the release of Bad from 14-3-3 
and permitting Bad dephosphorylation. Bad could then be retained in the membranes and 
translocate to the mitochondria upon a death signal (Hekman et al, 2006). Thus it could 
be possible that dephosphorylated Bad during combined androgen and LY294002 
treatment was associated with membranes and prevented from translocation to the 
mitochondria due to a lack of strong apoptotic signal. 
The BH3 domain of Bad is shown to be involved in the interaction with Bcl-xL or 
Bcl2 to relieve their inhibition on Bax family proteins during apoptosis (Zha et al, 1997; 
Kuwana et al, 2005). Earlier we presented data showing that androgen down-regulated 
the expression of Bcl2 in LNCaP cells whereas it up-regulated Bcl-xL expression which 
was detected in both mitochondrial and cytosolic fractions. It has been reported that 
apoptotic signal triggered the binding of Bad to cytosolic Bcl-xL and exposed its C-
terminal membrane anchor thereby promoting the translocation of Bcl-xL to the 
mitochondria to exert its anti-apoptotic activity (Jeong et al, 2004). Here we did not find 
any detectable interaction of Bad and Bcl-xL in the cytosol by co-immunoprecipitation. 
Thus Bcl-xL found in the cytosol upon androgen treatment was unlikely to be inhibiting 
Bad mitochondrial translocation by binding to and retaining Bad in the cytosol. 
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Although we could not find any detectable interaction of Bad and Bcl-xL in the 
cytosol, significant Bad and Bcl-xL interaction was found in the mitochondria of LNCaP 
cells. In addition, inhibition of PI3-K with LY294002 led to an increase in Bad-Bcl-xL 
interaction in the mitochondria which could be explained by the increase in mitochondrial 
translocation of dephosphorylated Bad and binding to Bcl-xL to promote apoptosis.  
  
4.7.3   Bak 
 Bak, another member of the Bax family, is localized only at the outer 
mitochondria membrane and upon an apoptotic trigger it undergoes a conformational 
change to become activated for its pro-apoptotic activity (Griffiths et al, 1999). Bak is 
likely to be involved in cell death induced by inhibition of PI3-K in LNCaP cells as 
treatment with LY294002 induced an increase in Bak activation as detected by the 
amount of Bak with an exposed N-terminal. In addition, a decrease in Bak expression by 
siRNA transfection inhibited LY294002-induced apoptosis, indicating that Bak, similar 
to Bax and Bad, was required for killing by inhibition of PI3-K. Treatment of cells with 
androgen and LY294002 inhibited the activation of Bak, thus suggesting that androgen 
could mediate the inhibition of LY294002-induced apoptosis by blocking Bak. Moreover, 
androgen inhibited the activity of caspase 3 induced by LY294002 to a level similar to 
that induced by LY294002 in Bak-repressed LNCaP cells. These results suggested that 
androgen-mediated inhibition of apoptosis could be attributed to the inhibition of Bak 
activation. Thus the inhibition of PI3-K in LNCaP cells resulted in apoptosis possibly by 
activating Bak and this could be blocked by the addition of androgen. 
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 A ‘displacement’ model whereby the BH3-only protein Bad competes with Bax 
for binding to Bcl-xL or Bcl2 and in turn frees Bax for homodimerization to execute cell 
death via mitochondrial dysfunction has been proposed (Yang et al, 1995). Another 
group suggested an alternative model whereby sequestration of BH3-only proteins by 
anti-apoptotic Bcl2 and Bcl-xL could result in inhibition of apoptosis by preventing Bax 
and Bak activation by the BH3-only proteins (Cheng et al, 2001). Our results from co-
immunoprecipitation assays showed that Bcl-xL interacted with both Bak and Bad but no 
interaction was found between Bak and Bad. Thus this ruled out the possibility of a 
heterotrimeric complex between Bcl-xL, Bak and Bad but Bcl-xL was most likely to 
form heterodimers with either Bak or Bad. In support of the ‘displacement’ model, Bak 
has been found to bind via its BH3 domain to Bcl-xL, but not to Bcl2, and activation of 
the BH3-only protein Bad in the presence of an apoptotic trigger could engage Bcl-xL 
thereby freeing Bak to carry out its pro-apoptotic functions (Willis et al, 2006).  
Indeed upon inhibition of PI3-K with LY294002, we demonstrated that Bcl-xL 
and Bak interaction decreased whereas, in contrast, Bcl-xL and Bad interaction increased 
relative to that in control cells. This could be due to the dephosphorylation of Bad 
induced by LY294002, causing an increase in the mitochondrial translocation of Bad and 
consequently an increase in its association with Bcl-xL, which then resulted in less Bcl-
xL available for binding to Bak. Unbound activated Bak was likely to oligomerize and 
mediate apoptosis which corresponded to the increase in caspase 3 activity and subG1 
population seen in the presence of LY294002.  
Several reports have recently provided evidence for the participation of Bcl-xL in 
blocking Bak-mediated apoptosis. It was reported that Bcl-xL interacted with Bak but not 
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Bax in LNCaP cells and this interaction between Bcl-xL and Bak was diminished upon 
an apoptotic trigger, suggesting that Bcl-xL could be inhibiting pro-apoptotic activity of 
Bak via heterodimerization in the absence of apoptotic stimulus (Castilla et al, 2006). In 
another study, it was revealed that the α-tocopheryl succinate exhibited its anti-tumour 
effect by disrupting the interaction between Bcl-xL and Bak in LNCaP cells which led to 
apoptosis of LNCaP cells. In that study, α-tocopheryl succinate was able to displace Bak 
bound to Bcl-xL by binding to the Bak peptide-binding site of Bcl-xL, thereby inhibiting 
Bcl-xL activity as an anti-apoptotic protein (Shiau et al, 2006). 
Bcl-xL was shown to play a critical role in androgen-mediated PI3-K independent 
cell survival. We postulated that androgen-induced up-regulation of Bcl-xL could be 
important for suppressing Bak activity triggered by inhibition of PI3-K. In fact an 
increase in Bcl-xL and Bak association was found in LNCaP cells treated with androgen 
and this interaction was not prevented in the presence of LY294002 unlike that in cells 
treated with LY294002 alone. Therefore the increase in Bcl-xL expression by androgen 
could most probably lead to increased complexing of Bcl-xL with Bak, thereby inhibiting 
oligomerization of Bak. Furthermore, Bcl-xL could also bind to Bad (translocated to the 
mitochondria) to prevent Bad-induced apoptosis in the presence of LY294002. 
LY294002-induced Bad translocation to the mitochondria might not be able to 
overwhelm the elevated levels of Bcl-xL induced by androgen, thus enabling sufficient 
Bcl-xL to bind to Bak and consequently blocking apoptosis. 
Research on the development of antagonists of Bcl2 family to induce apoptosis in 
tumour cells has been recently highlighted as overexpression of Bcl2 anti-apoptotic 
proteins have been shown to block cell death (Lebedeva et al, 2000). The main function 
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of anti-apoptotic Bcl2 proteins is to heterodimerize with their pro-apoptotic relatives and 
inhibit their death-inducing action. In order to generate inhibitors of anti-apoptotic 
proteins as therapeutic agents, molecular modeling of the interactions between Bcl2 
family members has been carried out to further understand their structural features (Pinto 
et al, 2004). Work to discover Bcl-xL inhibitors that target the protein-protein 
interactions has been on-going, and recently it has been discovered that terephthalamide 
derivatives which mimic the α-helical region of Bak BH3 domain was able to block the 
interaction of Bak and Bcl-xL by docking itself at the Bak BH3 domain-binding site of 
Bcl-xL (Yin et al, 2005). Hence it could be an interesting tool to test if such Bcl-xL 
inhibitor could abolish androgen-induced PI3-K independent survival in LNCaP cells, 
and further verify if the ability of Bcl-xL to bind and inhibit Bak is vital for cell survival. 
 
4.8   Summary: A model for androgen-mediated PI-3K independent cell survival in 
androgen-dependent prostate cancer 
 In recapitulation of the evidence presented thus far, we postulated a model for 
androgen-mediated PI-3K independent cell survival (Figure 32). In LNCaP cells grown in 
the presence of androgen, the AR signaling pathway is activated and leads to an increase 
in AR expression and its activity as a transcription factor. Through a yet undefined 
mechanism, AR causes an increase in STAT3 expression leading to an increase in its 
phosphorylation. Activated STAT3, one of the transcription factors for Bcl-xL, 
translocates to the nucleus, up-regulates Bcl-xL levels and causes an increase in 
expression of Bcl-xL in both the cytosol and mitochondria.  
 Discussion 100
Inhibition of PI3-K/AKT signaling pathway by LY294002 leads to the 
dephosphorylation and mitochondrial translocation of Bad. In addition, LY294002 also 
brings about an increase in Bak and Bax activation thus contributing to apoptosis. 
However, androgen-induced up-regulation of Bcl-xL can probably antagonize the effects 
of the pro-apoptotic Bcl2 members via heterodimerization, thereby mediating survival 
even when the essential PI3-K signaling pathway is blocked in LNCaP cells. The 
androgen-induced Bcl-xL can either associate with Bad to prevent its activation of 
apoptosis or with Bak to block its oligomerization and thus mitochondrial dysfunction. 








Figure 32. A schematic model for androgen-mediated PI3-K independent cell 















































4.9   Cell survival in androgen-indepedent prostate cancer: PI3-K/Akt and Erk 
signaling pathway 
 Early stages of prostate cancer are generally androgen-dependent for its growth 
and proliferation. Androgen ablation therapy can lead to the regression of such tumours 
and it is used to treat the initial stage of prostate cancer in men. However, it has been 
observed that after prolong period of androgen ablation, prostate cancer can develop into 
an advanced androgen-independent stage when deprivation of the hormone is no longer 
an effective treatment. Several theories have been proposed to explain for the 
advancement of prostate cancer to become androgen-independent but the mechanism 
behind has yet to be clearly understood (Pilat et al, 1999). 
 In our study, we used the androgen-dependent prostate cancer cell line LNCaP as 
a model to study the mechanism of androgen-mediated cell survival. Our laboratory has 
also derived a sub-line of LNCaP, through prolonged passages, which has lost its AR 
expression and it could be useful as a tool to learn more about the survival mechanisms of 
androgen-independent prostate cancer.  
 In the characterization of the AR-negative LNCaP cell line, we have found that 
the PI3-K/AKT signaling pathway was constitutively active similar to the wild type 
LNCaP cells albeit at a lower level. However, in contrast to AR-expressing LNCaP cells, 
the MAPK pathway seemed to be constitutively activated in AR-negative LNCaP cells. 
Another group has previously reported generating an androgen-independent high passage 
LNCaP sub-line, which had constitutive activation of the Src/MEK/ERK/CREB 
signaling, resulting in their androgen-independence and resistance to apoptosis (Unni et 
al, 2004). Thus both PI3-K/AKT and MAPK pathways could likely participate in survival 
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of AR-negative LNCaP cells and enable better survival although we did not show if this 
could directly contribute to androgen-independency. More tests are required to further 
understand the mechanism of developing androgen independence and how it could 
engage the MAPK signaling.  
 Besides the constitutive activation of both the PI3-K/AKT and MAPK signaling 
pathway in androgen-independent LNCaP cells, we also showed that cross-talk was likely 
to exist between these two survival pathways. Treatment of AR-negative LNCaP cells 
with specific PI3-K inhibitor such as LY294002 and wortmannin, in addition to blocking 
PI3-K/AKT signaling, led to the inactivation of the MAPK pathway as seen from the 
dephosphorylation of MEK/ERK/p90rsk module and downstream Bad at serine75 (a site 
known to be phosphorylated by p90rsk). Furthermore, activation of ERK was also 
reduced with the repression of PDK1 but not with repression of AKT, a PDK1 
downstream target. Thus it could be highly possible that the cross-talk of the two survival 
pathways could be linked between PDK1 and MEK. Previously it has been found that 
AKT could interfere with MAPK signaling through phosphorylation-induced inhibition 
of Raf (Zimmermann and Moelling, 1999) although we did not test the involvement of 
Raf, which is upstream of MEK in MAPK signaling, in the cross-talk of the survival 
pathways. However, in support of our findings, it was reported that PDK1 could bind to 
and directly phosphorylate MEK in vivo (Sato et al, 2004).  
 Although the repression of PDK1 in AR-negative LNCaP cells produced similar 
results to treatment with PI3-K inhibitor in the inactivation of the MAPK pathway, the 
repression of PDK1 nor AKT, in the absence of growth factors, did not induce apoptosis 
unlike when cells were exposed to LY294002. It could be possible that the efficiency of 
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repression of PDK1 or AKT by siRNA transfection was insufficient to reduce their 
expression low enough to inhibit the survival pathways and induce apoptosis. Another 
possible explanation could be that the PI3-K inhibitor, besides blocking the activation of 
AKT and ERK, also affected other survival proteins probably a kinase or phosphatase 
which could be involved in the phosphorylation of Bad since LY294002 induced Bad 
dephosphorylation whereas PDK1 repression did not. Hence the use of chemical and 
molecular approach to study effect on signaling molecules might produce different results 
and care has to be taken in their analysis. 
 
4.10   Computational modeling to study cross-talk of signaling pathways in 
androgen-independent LNCaP 
 Signaling pathways have been studied in-depth as distinct cascade but protein-
protein interactions and cross-talks between pathways exist within the cell. Therefore the 
study of cell signaling molecules as a whole system of network will better reflect the 
dynamics of the cells and aid in the understanding of molecular mechanisms of various 
signaling pathways.  
In our current study, computational modeling of the PI3-K/AKT and MAPK 
signaling pathway in AR-negative LNCaP cell line was used to study the possible cross-
talk of the pathways and to aid in refinement of hypothesis through simulation reactions. 
The recently introduced Hybrid Functional Petri Net (HFPN) was adopted as our 
modeling framework and a decompositional approach, which exploits the structure of a 
large pathway model to break it into smaller components, to the parameter estimation 
problem in signaling pathway modeling has been proposed. We constructed the model 
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based on experimental data and ran simulation on the model by manipulating the 
parameters of interest (Koh et al, 2006). An example would be the change to the PDK1 
expression level in AR-negative LNCaP cells and simulated results showed that the 
lowering PDK1 level led to an increase in the inhibition of ERK. This was well-
correlated with our experimental result of the repression of PDK1 by siRNA technique. 
Thus these suggested the ability of our model to correctly predict results from simulation 
although it would still be critical to validate such simulation data experimentally. 
Nonetheless, computational modeling of the pathways could be extended to study other 
pathways and investigate the interaction of various signaling mechanisms.  
 
4.11   Conclusion 
Understanding the escape from apoptosis and uncontrolled proliferation of tumour 
cells is fundamental to designing therapy for the cure of cancer. In our current study of 
the prostate cancer model, we examined the existence of a PI3-K/AKT independent 
survival pathway in the LNCaP cell line induced by androgen. PI3-K/AKT signaling is 
one of the major survival pathways in LNCaP and its inhibition will lead to cell death. 
We showed that androgen could induce an increase in the anti-apoptotic protein Bcl-xL 
expression through STAT3 up-regulation and activation. The increase in Bcl-xL was 
shown to be critical in antagonizing the activation of pro-apoptotic Bcl2 family of 
proteins, such as Bad and Bak, induced by the inhibition of PI3-K signaling. Hence 
elimination of the prostate cancer cells would require more than the inhibition of the PI3-
K/AKT survival pathway.  
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Besides androgen, other growth factors such as serum and EGF have also been 
implicated in mediating PI3-K/AKT independent survival and contributing to LNCaP 
cells resistance to apoptosis. Thus the challenge in the treatment of prostate cancer will 
be to understand the mechanisms that lead to the inhibition of apoptosis and to identify 
signaling targets which can compromise tumour cells resistance to cell death. 
 Androgen can mediate a survival pathway involving the up-regulation of Bcl-xL 
in LNCaP cells. Androgen deprivation has been used as one of ways to treat early stages 
of prostate cancer but this proved to be difficult as prolonged treatment could cause the 
prostate cancer to advance to an androgen-independent stage whereby androgen 
deprivation could not curb its growth. Here we showed constitutive activation of the 
MAPK signaling in addition to PI3-K/AKT signaling in AR-negative LNCaP cells and 
that there was likely cross-talk between these two survival pathways, based on our 
experimental and simulated data from the computational model. Yet how androgen-
independence could lead to the engagement of the MAPK signaling would require further 
investigation. Therefore it is also essential to better understand the development of 
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